Aviva Life & Pensions Ireland (ALPI) dac

Solvency and Financial Condition Report 2019







Intro	duction	4
A. I	Business and Performance	6
A.1.	Business	6
A.2.	Underwriting Performance	9
A.3.	Investment Performance	10
A.4.	Performance of Other Activities	11
A.5.	Any Other Information	11
B	System of Governance	12
B.1.	General Information On The System Of Governance	12
B.2.	Fit and Proper Requirements	17
B.3.	Risk Management System Including The Own Risk And Solvency Assessment	17
B.4.	Internal Control System	20
B.5.	Internal Audit Function	21
B.6.	Actuarial Function	22
B.7.	Outsourcing	22
B.8.	Any Other Information	23
C. I	Risk Profile	24
C.1.	Underwriting risk	24
C.2.	Market risk	26
C.3.	Credit risk	27
C.4.	Liquidity risk	28
C.5.	Operational risk	29
C.6.	Other Material Risks	30



C.7.	Ar	y Other Information	30
	C.7.1.	Sensitivities to Key Factors	30
	C.7.2.	Prudent Person Principle	30
	C.7.3.	Other Information	31
D.	Valua	tion for Solvency Purposes	32
D.1.	As	sets	33
D.2.	Te	chnical Provisions	34
D.3.	Ot	her Liabilities	38
D.4.	Alt	ernative Methods for Valuation	40
D.5.	Ar	y Other Information	40
E.	Capit	al Management	42
E.1.	Ov	vn Funds	42
E.2.	So	lvency Capital Requirement and Minimum Capital Requirement	45
E.3.	Du	ration-Based Equity Risk Sub-Module	47
E.4.	Int	ernal Model Information	47
E.5.	No	on-Compliance with the MCR and Non-Compliance with the SCR	47
E.6.	Ar	y Other Information	47
Арр	endix	1: Balance Sheet	53
Арр	endix	2: Premiums, Claims and Expenses by Line of Business	55
Арр	endix	3: Life and Health SLT Technical Provisions	56
Арр	endix	4: Impact of Long Term Guarantees and Transitional Measures	57
Арр	endix	5: Own Funds	58
Арр	endix	6: Solvency Capital Requirement	60
Арр	endix	7: Minimum Capital Requirement	61

INTRODUCTION

1.1. AVIVA LIFE & PENSIONS IRELAND

Aviva Life & Pensions Ireland dac ("ALPI", "ALPI DAC" or "the Company") is an Irish life assurance company writing life and pensions business. It provides a range of life insurance and savings products in Ireland, including income protection, mortgage protection, pensions, group protection, investment bonds, and regular premium savings products. In addition, the Company also insures a block of overseas European life assurance business, which was previously written in Aviva Life & Pensions UK Limited (UKLAP) prior to Brexit.

Aviva Life & Pensions UK Limited purchased Friends First or "FFLAC" from Dutch insurance group Achmea on 31 May 2018. The acquisition was approved by the Competition and Consumer Protection Commission and by the Central Bank of Ireland. FFLAC was renamed Aviva Life & Pensions Ireland (ALPI) date on 29 March 2019.

Also, on 29 March 2019, the existing business of Aviva Life & Pensions Ireland branch (ALPI branch) was transferred into ALPI dac from UKLAP, together with a block of European life assurance business, ensuring this business could continue to be administered within the EU following Brexit.

1.2. THIS REPORT

This Solvency and Financial Condition Report (SFCR) has been prepared in line with the requirements of the Solvency II regulations, to assist the various stakeholders of Aviva Life & Pensions Ireland dac in understanding the nature of its business, how it is managed and its solvency position. This report discloses the eligible own funds, required capital and solvency ratio of the Company according to the Solvency II Standard Formula for the period ending 31 December 2019.

The information as disclosed in this report is prepared in conformity with the Solvency II legislation and the guidance provided by EIOPA. This SFCR report covers the Business and Performance of the Company, its System of Governance, Risk Profile, valuation for Solvency Purposes and Capital Management. The party with ultimate responsibility for all of these matters is the Company's Board of Directors, with the assistance of various governance and control functions it has put in place to monitor and manage the business. The Solvency II Standard Formula is used throughout to determine the Solvency Capital Requirements.

The Company's financial year runs to 31 December each year and it reports its results in Euro. Amounts in this report are presented in €1,000's. Due to this, rounding differences may occur. These rounding differences have no material impact. Throughout this document, figures quoted are consistent with those previously reported to the Irish regulator.

1.3. EXECUTIVE SUMMARY

For a summary of each of the sections in this report, please refer to the following:

SECTION A. BUSINESS AND PERFORMACE

This section provides information on ALPI DAC's business, organisational structure and financial performance. It also refers to significant events during 2019, including the renaming of FFLAC to ALPI dac and transfer of ALPI branch and European business from UKLAP in March 2019.

SECTION B. SYSTEM OF GOVERNANCE


The Company's governance and risk frameworks are detailed in this section of the report. There have been significant changes to these frameworks in the reporting period, following the Company's change of ownership, which took place in 2018.



SECTION C. RISK PROFILE

This section explains the Company's main risk exposures together with how we assess, mitigate and monitor them. The risks outlined include underwriting, market, credit, liquidity and operational risk.

The Company's risk profile is measured by the Solvency Capital Requirement (SCR), which is calculated in accordance with the Standard Formula. The following charts provide a split of the Basic Solvency Capital Requirement (BSCR) by risk module for Year End 2019 and 2018, without allowing for diversification.



SECTION D. VALUATION FOR SOLVENCY PURPOSES

This section deals with how we value the Company's assets and liabilities for the purposes of Solvency II and shows the values of these assets and liabilities at 31 December 2019 as compared with the prior year end.

SECTION E. CAPITAL MANAGEMENT

The capital held by the Company is outlined in this section, together with the SCR.

The Company uses the Standard Formula to calculate its SCR. The Company's SCR at 31 December 2019 is €476.7m. This is covered by €716.9m of eligible capital, providing a Solvency II surplus of €255.3m and a Solvency II coverage ratio of 150%.

SOLVENCY RATIO				
	2019	2018	Variance	
Eligible Own funds	716,912	245,258	471,654	
Required capital	476,652	148,353	328,300	
Surplus	240,259	96,905	143,354	
Ratio (%)	150%	165%	-15%	

A. BUSINESS AND PERFORMANCE

This section of the report outlines business structure, activities and performance of Aviva Life & Pensions Ireland dac over the year to 31 December 2019.

A.1. BUSINESS

GENERAL

ALPI DAC is an Irish life assurance company writing life and pensions business which has been helping our customers look after their protection, pension and investment needs for over 180 years. We are one of Ireland's most established life assurance companies with a reputation for reliability and efficiency and are committed to our approximately 250,000 Irish customers. We manage assets totaling \leq 15 billion and generated total premiums of \leq 1,394 million in 2019.

ALPI DAC is a Designated Activity Company and business is primarily written within the Republic of Ireland, with some overseas business also written in Belgium, France, Germany, Iceland, and Sweden. The Company's operating address and registered office is:

Aviva Life & Pensions Ireland dac One Park Place Hatch Street Dublin 2 D02 E651 Ireland

UKLAP purchased Friends First from Achmea on 31st May 2018. ALPI dac is now fully owned by its parent company, Aviva Life and Pensions UK Limited, which is ultimately owned by Aviva plc. Aviva is one of the largest and most secure financial services providers in the world. With over 33 million customers in 16 countries worldwide, they have been meeting the needs of their Irish customers since 1780. Today, Aviva provide a wide range of insurance and savings products – from life insurance to pensions, investments and asset management. Our market-leading life and pensions propositions enable us to continue to service over 1 million Irish customers, helping them save for their future, draw a secure income in retirement and insure what matters most to them.

Aviva is the UK's largest insurer and they also have a strong international presence in Europe, Canada and Asia. Its head office is located at:

St. Helen's, 1 Undershaft, London EC3P 3DQ, England

The group structure is summarised in chart 1 below, while chart 2 shows the structure of ALPI dac as at 31 December 2018.

Chart 1: Group Structure - Aviva





Chart 2: Group Structure – Aviva Life & Pensions Ireland dac



ALPI dac is regulated by the Central Bank of Ireland (CBI). The CBI's address is:

Central Bank of Ireland New Wapping Street North Wall Quay Dublin 1 Ireland

Aviva plc is regulated by UK Prudential Regulation Authority (PRA) with an address at:

20 Moorgate London EC2R 6DA United Kingdom

ALPI dac's external auditor for the financial year end 2019 was PriceWaterhouseCoopers (PwC), One Spencer Dock, North Wall Quay, Dublin 1.

Aviva Life and Pensions Ireland dac has registered offices at One Park Place, Hatch Street, Dublin 2.

SIGNIFICANT EVENTS

Acquisition and Part VII transfer

In November 2017, Aviva's purchase of Friends First Life Assurance Company dac and its subsidiaries announced. This purchase was subject to a 'Change of Control' application to the Central Bank of Ireland (CBI) which was granted on 23 May 2018. Following the approval, ownership of FFLAC was transferred from Aviva Group Holdings to Aviva Life and Pensions UK Limited (UKLAP) and on 31st May 2018 Friends First became a wholly owned subsidiary of UKLAP.

On 29 March 2019 an insurance portfolio transfer of a subset of business of Aviva Life and Pensions UK Limited under Part VII of the Financial Services and Markets Act 2000 was made to Friends First. The transfer took place at 22:59 on 29 March 2019 and Friends First was renamed to Aviva Life and Pensions Ireland dac (ALPI). Under the Part VII transfer, UKLAP was required to make a capital injection to ALPI dac to ensure ALPI dac is capitalised to an SCR Ratio of 150% as at the effective date. During 2019, the Company received a €282m capital contribution from Aviva Life and Pensions UK Limited in relation to this recapitalisation.

COVID-19 Pandemic

On 11 March 2020, the World Health Organisation declared the outbreak of novel coronavirus disease, COVID-19, a global pandemic. Governments in affected areas have imposed a number of measures designed to contain the outbreak, including business closures, travel restrictions, stay at home orders and cancellations of gatherings and events. The spread of COVID-19 has resulted in an economic downturn in jurisdictions in which the Company operates and the global economy more widely, as well as causing increased volatility and declines in financial markets. If the pandemic is prolonged, or further diseases emerge that give rise to similar effects, the adverse impact on the global economy could be deepened and result in further declines in financial markets.

As an insurer ALPI dac is impacted by the COVID-19 pandemic through its life protection products as a result of increased mortality and income protection and critical illness products as a result of increased morbidity. The Company's balance sheet exposure has been reviewed and actions are being taken to further reduce the sensitivity to economic shocks. Notwithstanding the Company's robust capital and liquidity position and the operational and financial actions being taken, the deterioration in the situation has adverse implications arising from the impacts on financial markets, insurance exposures and operations. As the situation is rapidly evolving it is not practicable to quantify the potential financial impact of the outbreak on the Company.

Insurance Portfolio Transfer

In March 2020 a related company, Area Life International Insurance DAC made an application to the High Court under Section 13 of the Assurance Companies Act 1909, Section 36 of the Insurance Act 1989 and Regulation 41 of the European Union (Insurance and Reinsurance) Regulations 2015. The application asked the court to sanction the transfer of the life assurance business of Area Life International Insurance DAC to Aviva Life & Pensions Ireland DAC. This was approved by the High Court in March 2020 and took effect on 1st April 2020.

The total assets transferred from Area Life International Insurance DAC to the Company is yet to be determined at the publication of this report. The total assets at 31 December 2019 is €60m as disclosed in the financial statements of Area Life International Insurance DAC.

BUSINESS ACTIVITIES

ALPI dac's key mission is to provide tailored protection, retirement and investment solutions that provide our customers with benefits when they need them most. We provide a range of flexible life and savings products, including:

- Individual income protection, providing an alternative income if illness or injury stops you from working long-term
- Individual mortgage and life insurance protection, providing security in the event of illness, accident or death



- Income protection and life insurance protection for Groups (usually employees of specific companies) known as group risk business
- Pension funding products, including group, personal and executive pensions, annuities and retirement drawdown products known as approved retirement funds (ARFs), allowing our customers to really enjoy their retirement when it comes
- Savings and investment products, including lump sum bonds and regular premium savings products, to help our customers fund the future they want

Our products and services in Ireland are introduced to customers solely by Financial Brokers who can help in identifying financial needs and provide advice on the right products to meet those needs now and in the future.

BUSINESS DEVELOPMENT

The Irish economy experienced broad growth in 2019 and also experienced low inflation and low interest rates. Consumer spending remained strong as the economy approaches full employment. However the political landscape remains volatile as the government tries to mitigate the impact of Brexit to the Irish economy. Despite these Brexit concerns, the insurance industry experienced an increase in 2019 of 4% in new sales (excluding investment only business), measured on an Annual Premium Equivalent (APE) basis, the industry benchmark.

A.2. UNDERWRITING PERFORMANCE

Gross premium income (insurance contracts) for the company increased significantly to ≤ 361 m for the year from ≤ 146 m in 2018 driven by the consumption of the additional businesses under the Part VII transfer from Aviva Life & Pensions UK Ltd on 29th March 2019. Similarly, contributions to Investment Contracts also increased significantly to $\leq 1,033$ m (2018: ≤ 488 m) with the additional business forming part of the Company for 9 months of 2019. Gross claims incurred for 2019 amounted to ≤ 304 m (2018: ≤ 199 m). Gross consideration paid out in respect of investment contracts was ≤ 985 m in the year (2018: ≤ 341 m).

New sales were profitable on best estimate assumptions. Value of New Business (VNB) for the full year 2019 was \notin 9.2m, lower than the 2018 figure of \notin 12.0m.

The table below includes premiums, claims and expenses in relation to insurance and investment contracts, split by business line, in line with guidance on the contents of QRT S.05.01 Premiums, Claims and Expenses:

UNDERWRITING PERFORMANCE	BY LINE OF BU	JSINESS				€ 1,000
	HEALTH		INSURANCE \	WITH PROFIT	UNIT LI	NKED
	2019	2018	2019	2018	2019	2018
Gross written premiums	66,609	54,033	6,110	7,210	1,094,012	501,042
Net earned premiums	53,240	49,909	-70,170	7,205	127,714	498,543
Claims incurred (net)	37,185	33,254	119,304	54,286	856,701	369,262
Expenses incurred	13,721	14,573	2,449	3,398	101,617	59,958
Other expenses	0	0	0	0	0	0
Total Expenses	13,721	14,573	2,449	3,398	101,617	59,958
		-	OTHE	R LIFE	TOT	AL
			2019	2018	2019	2018
Gross written premiums			226,859	71,492	1,393,590	633,777
Net earned premiums			-141,414	45,679	-30,631	601,336
Claims incurred (net)			98,372	34,005	1,111,561	490,806
Expenses incurred			42,957	16,444	160,743	94,373
Other expenses			0		-	0
Total Expenses			42,957	16,444	160,743	94,373

The table below includes premiums, claims and expenses in relation to insurance and investment contracts, split by geographical

areas, in line with guidance on the contents of QRT S.05.01 Premiums, Claims and Expenses:

on DE Li chi chi con la							
	FRANCE	IRELAND	BELGIUM	GERMANY	ICELAND	SWEDEN	TOTAL 2019
Gross written premiums	829	1,347,683	7,800	33,103	3,355	820	1,393,590
Gross claims incurred	5,813	1,190,709	7,628	17,856	3,133	3,421	1,228,561
Total Expenses	0	160,743	0	0	0	0	160,743

UNDERWRITING PERFORMANCE BY GEOGRAPHICAL AREAS

No comparative figures are available for 2018 as all underwriting was restricted to Ireland in 2018. The business written outside of Ireland results from the Overseas Life Assurance Business (OLAB) portfolio which was accepted as part of the Part VII transfer during 2019. This business is 100% reinsured to Aviva Life and Pensions UK Ltd.

A.3. INVESTMENT PERFORMANCE

Investment return comprises all investment income, realised investment gains and losses and movements in unrealised investment gains and losses.

A significant portion of the Company's insurance business relates to unit-linked policies and policies written into with-profits funds. For these lines of business excess investment performance is effectively passed on to our policyholders. Outside of these lines of business the Company holds assets which are expected to perform in line with our Best Estimate Liabilities. Hence, any changes to asset values are 'matched' by changes to policyholder liabilities.

The following tables outline the investment performance of ALPI dac's unit-linked and non-linked investments in 2019, with a comparison to the previous year. The tables are prepared as per the guidance for QRT S09.01.

Income from UNIT-LINKED INVESTMENTS

							€ 1,000
ASSET CLASS	DIVIDENDS	INTEREST	RENT	TOTAL INCOME	GAINS AND LOSSES	TOTAL 2019	TOTAL 2018
Equity and Unit Trusts	30,267	0	0	30,267	565,037	595,305	-87,179
Fixed Income	0	13,852	0	13,852	30,341	44,193	-16,192
Property	0	0	43,374	43,374	10,289	53,663	36,770
Cash and deposits	0	-1,653	0	-1,653	-1,773	-3,425	550
Derivatives	0	0	0	0	-7,069	-7,069	0
Other Investments	0	0	0	0	287	287	0
Grand Total	30,267	12,200	43,374	85,841	597,112	682,952	-66,051

Total investment income for unit-linked investments in 2019 was a gain of €682.95m in comparison to a loss of €66.05m in 2018. The main reason for this large change was due to unrealised gains and losses in the Equity and Unit Trusts portfolio.

INCOME FROM NON-LINKED INVESTMENTS

							€ 1,000
ASSET CLASS	DIVIDENDS	INTEREST	RENT	TOTAL INCOME	GAINS AND LOSSES	TOTAL 2019	TOTAL 2018
Equity and Unit Trusts	1,240	0	0	1,240	9,959	11,199	17,546
Fixed Income	0	78,420	0	78,420	107,839	186,259	5,989
Property	0	0	410	410	368	778	-579
Cash and deposits	0	78	0	78	-111	-33	-200
Derivatives	0	-4,521	0	-4,521	29,368	24,847	0
Other Investments	0	0	0	0	8,327	8,327	0
Grand Total	1,240	73,976	410	75,626	155,752	231,378	22,756

As can be seen from the above table, total investment income for non-linked investments in 2018 was €231.38m in comparison with €22.76m in 2018, the change being largely due to unrealised gains and losses in the fixed income portfolio.

Total investment return on unit-linked and non-linked investments has increased to €914.33m in 2019, compared to a loss of €43.30m in 2018.

Interest income on debt securities and other fixed income securities, loans secured by mortgages, other loans and deposits with credit institutions is recognised using the effective interest method.

Dividends are included as investment income on the date that the shares become quoted ex-dividend. Rents and interest income and expenses are included on an accruals basis.

Realised gains and losses on investments are calculated as the difference between net sales proceeds and purchase price.

Unrealised gains and losses on investments recognised in the year represent the difference between the fair value at the balance sheet date and their purchase price or, if they have previously been fair valued, their fair value at the last balance sheet date. The movement in unrealised gains and losses recognised in the year also includes the reversal of unrealised gains and losses recognised in earlier accounting periods in respect of investment disposals in the current period.

A.4. PERFORMANCE OF OTHER ACTIVITIES

Nothing to report.

A.5. ANY OTHER INFORMATION


Information presented in Section A of this report represents the performance of the business as reported in the Company's financial statements for the 12-month period to 31 December 2019. As referred to above it is not practicable to quantify the potential financial impact of the outbreak on the company at this stage.

B. SYSTEM OF GOVERNANCE

B.1. GENERAL INFORMATION ON THE SYSTEM OF GOVERNANCE

COMPANY STRUCTURE

The Company has one policyholder fund with four sub-funds and a shareholder fund.



Participating Fund (90:10)

The business in the Participating Fund is conventional with profits business (both life and pensions), non-profit life assurance and pension business (written up to March 1996), and the unitised with profits investment component of unit linked policies written in the Other Business Fund. The fund continues to write increments to group life and pension schemes. It also continues to write immediate annuities.

The shareholders are entitled to transfers from the Participating Fund equal to 10% of the distributed surplus each year. However, the shareholders are liable to meet any shortfall.

Closed Fund (100:0)

This is the conventional business taken over from National Mutual Life Assurance Company in 1995. The fund is closed to new business. The shareholders have no entitlement to any of the surplus in the Closed Fund. There are guarantees that limit the expenses and tax, which can be charged to the Closed Fund.

Irish With Profit Fund (IWPF) (90:10)

This fund contains the with-profit liabilities of former Irish branch of Aviva Life & Pensions UK Ltd business and was transferred into ALPI dac on 29 March 2019. This fund operates on a 90:10 basis. However, there is an inherited estate within the fund which is not currently being distributed.

Other Business Fund (OBF) (0:100)

This consists of conventional life and pension non-profit business, unit linked business and conventional Income Protection. Shareholders are entitled to 100% of any surplus arising at each statutory valuation. A "With Profits" fund choice is available on many policies. Where this fund is selected the investment component of each premium is passed to (reinsured into) the Participating Fund or the Irish With Profit Fund (IWPF).

Some of the unit linked funds provide investment performance guarantees namely the "With Profits" fund funds and "Protected Equity" funds. The investment performance guarantees on Trackers and on most Protected Equity funds are provided by third parties – the Company is not obliged to meet the guarantees

The OBF continues to write regular and single premium unit-linked life and pension business. The OBF also writes regular premium term business (including critical illness), regular premium Income Protection business and group life and Income Protection risk schemes.

The Overseas Life Assurance Business (OLAB) that was accepted as part of the Part VII transfer is included within the Ordinary Business Fund. This business includes a mix of unit-linked, non linked protection, and with-profits business. However, no ring-fencing applies from the Company's perspective, as the business is 100% reinsured to Aviva Life & Pensions UK Ltd.

Shareholders Fund (0:100)


This fund holds the assets and liabilities not attributed to the long-term business funds.

Organisational structure

Aviva Group Holdings Limited acquired Friends First Life Assurance Company dac on 31 May 2018 and immediately transferred the company to its current parent, Aviva Life & Pensions UK Limited. The structure of the Company (ALPI) is represented graphically in a subsection of Chart 2 in Section A.1. The Participating, Other Business, Closed, IWPF and Shareholder Funds are included in the company structure. All other companies exist for the purpose of managing property assets.

Framework of the Board and its Committees

The Board operates in accordance with its Terms of Reference and also in compliance with the Corporate Governance Requirements for Insurance Undertakings, 2015 as issued by the Central Bank of Ireland. In addition to setting out the duties and responsibilities of the Board and how it governs itself and its Committees, this Chart sets out how authority is delegated throughout the Company. The delegated authorities framework sets out the system of governance in the Company in terms of the powers and responsibilities reserved by the shareholder or delegated by it to the Board, and thereafter delegated to the Group Chief Executive and management.



Delegations of authority are mechanisms by which the Company enables senior management and delegated individuals to act on behalf of the company and to fully understand their own authority levels and the limits under which they operate. This is a key element in the effective governance and management of the Company and provides formal authority to that officer to commit the Company and/or incur liabilities for the Company.

The Company Board

The Board is the supervisory and management body of the Company. The Board ensures that the Company is operated to maximise stakeholder value and operated in accordance with local law, the articles of association of the Company and the Board Terms of Reference (Legal Framework).

Where the Company adopts policies and procedures developed at group level, the Board satisfies itself that such policies or procedures meet all of the requirements of the Corporate Governance Requirements for Insurance Undertakings, 2015.

General Roles and Responsibilities of the Board

The Board is responsible for overseeing and approving the Company's strategic and operating objectives. It also ensures that effective audit, risk management and compliance systems are in place to protect the Company's assets and to minimise the possibility of the Company operating beyond legal or ethical requirements or beyond acceptable risk parameters. The Board operates in accordance with the Board Terms of Reference which the Board reviews and updates at least annually and more regularly, if required.

The Board has:

- The necessary knowledge, skills, experience, expertise, competencies, professionalism, fitness, probity and integrity to carry out their duties;
- A full understanding of the nature of the Company's business, activities and related risks;
- A full understanding of their individual direct and indirect responsibilities and collective responsibilities; and
- An understanding of the Company's financial statements.

Part of the Board's responsibilities include:

- Management of the amounts, types and distribution of both internal capital and own funds to ensure they adequately cover the risks of the Company;
- Overseeing the strategy for the on-going management of material risks including inter alia liquidity risk;
- Ensuring the existence of a robust and transparent organisational structure with effective communication and reporting channels;
- Ensuring that the remuneration framework is in line with the risk strategies of the Company; and
- Ensuring the existence of an adequate and effective internal control framework that includes well-functioning risk management, compliance and internal audit functions as well as an appropriate financial reporting and accounting framework.

Matters which are significant, which fall outside the normal course of business or which Senior Management believe the Board would need to be aware of, are presented on as a matter of course to the Board.

The Board agrees the Company's strategic aims, ensures that the necessary financial and human resources are in place for the Company to meet its objectives and reviews management performance at least quarterly. The Board sets the Company's values and standards and ensures that its obligations to its shareholders and others are understood and met.

The Board may delegate authority to sub-committees or management to act on behalf of the Board in respect of certain matters but, where the Board does so, it has mechanisms in place for documenting the delegation and monitoring the exercise of delegated functions. The Board does not abrogate its responsibility for functions delegated.

The Board is supported by the Audit Committee and the Risk Committee in fulfilling its oversight responsibilities in relation to:

- The effectiveness of internal controls;
- The effectiveness of the internal audit function;
- The effectiveness of the external audit process;
- The integrity of financial reporting;
- The safeguarding of the Company assets;
- The effectiveness of risk management;
- Compliance with laws, regulations and contractual obligations; and
- Compliance with Aviva Group's business standards.



The role of each Committee is set out in a Terms of Reference for each, previously agreed by the Board and reviewed regularly, at least annually. The Board ensures that it receives timely, accurate and sufficiently detailed information from the Committees each quarter.

The Board Terms of Reference sets out the following waterfall of delegated powers:

- 1. The Board reserves certain matters for its own consideration and may then delegate on an ongoing basis certain aspects of its powers to the Chief Executive, established Committees (in line with their terms of reference), Senior Management or Delegated Individuals.
- 2. The Board shall be responsible for appointing a Chief Executive Officer and Senior Management with appropriate integrity and adequate knowledge, experience, skill and competence for their roles.
- 3. The Board shall be responsible for endorsing the appointment of people who may have a material impact on the risk profile of the Company and monitoring on an ongoing basis their appropriateness for the role.

Structure of the Board and its Committees

The structure of the Company Board and Board Committees is summarised in the table below.

Director's Name	Status on Board	Membership and status on Sub- Committees
Paul Raleigh (Irish)	Chairman	Nomination – Chair Remuneration - Member
Tom Browne (Irish)	Chief Executive Officer	Nomination - Member
Tracy O'Rourke (Irish)	Independent Non-Executive Director	Audit – Member Risk – Chair Nomination – Member Remuneration - Member
David Swanton (Irish)	Independent Non-Executive Director	Audit – Chairman Risk – Member Nomination – Member Remuneration - Chairman
David Elliot (British)	Non-Executive Director	Audit – Member Risk - Member
Patrick Dixneuf (French)	Non-Executive Director	-
Virginia Lawlor (Irish)	Executive Director	Chief Financial Officer

In accordance with the Directors' Compliance Statement:

- The management of the Company believe that they have established such processes and procedures as are necessary to maintain proper records and that an adequate system of controls is maintained over these transactions and records.
- These procedures and controls have been subject to audit in 2019 by both the Group Internal Audit Function on an ongoing basis and external audit by PricewaterhouseCoopers through the year-end audit process. Audit reports by both have been circulated to the appropriate management and actions are tracked and reported to the Audit Committee.
- The financial results and balance sheet position are reported on a quarterly basis to the shareholder and to the Board. These quarterly returns undergo a high level of review at the different stages of their production to ensure that all figures are reasonable and accurate. These reviews have been consistently performed during 2019, allowing for expansion of the scope to include all business of ALPI dac.



Directors' Fees

Generally, directors who provide their services and do not otherwise receive a salary from the Company, or the Aviva Group, receive a fee for their services as disclosed in the Statutory Accounts.

Remuneration Policy

The Company's remuneration policies are fully aligned with those of Aviva Group. For the company it is important to have a reward framework that prevents excessive risk taking, aligns interests to those of the Company, ensures we attract and retain people with the talent needed to maintain and deliver on the strategy and is compliant with regulation and legislation.

Principles of the Company's Remuneration Policy

- Provides of a competitive total remuneration package which supports the attraction, development, and retention of employees; reinforces our values and behaviours; and is in line with appropriate regulatory and legal practice.
- Promotes both annual and long-term strategic objectives by setting stretching and appropriate targets.
- Differentiates reward based on performance; incorporates Group, business unit and individual performance including financial and non-financial objectives
- Aligns senior executives' and senior managers' remuneration with the interests of shareholders and other key stakeholders
- Remuneration directly aligned to risk; reward policies promote sound and effective risk management and do not encourage risk-taking that exceeds the risk tolerance of the company and are subject to Malus and Clawback policies.

Pension Arrangements

The Company operates a Defined Contribution Pension Scheme for all staff into which both employees and employer contribute on an agreed basis. The Scheme is administered by Willis Towers Watson on behalf of the Company and Trustees.

Many employees also have deferred entitlements from a now frozen Defined Benefit Scheme.

Material Transactions with Shareholders during 2019

On 29 March 2019 an insurance portfolio transfer of a subset of business of UKLAP under Part VII of the Financial Services and Markets Act 2000 was made to the Company – this portfolio includes both the Irish branch of UKLAP, in addition to a portfolio of European life assurance business written in Belgium, France, Germany, Iceland, and Sweden.

Under the Part VII transfer, UKLAP was required to make a capital injection to ALPI dac to ensure ALPI dac is capitalised to an SCR ratio of 150% as at the effective date (29 March 2019). During 2019, the Company received capital injections of €282m from UKLAP under the provisions of the Scheme of Transfer.

As part of the Part VII transfer, the European life assurance business transferred from UKLAP was in turn 100% reinsured back to UKLAP. This represented an internal reinsurance transaction.

The Company made a dividend payment of €15m to the parent (Aviva Life and Pensions UK Ltd) on 25 February 2020 in respect of performance during 2019.

B.2. FIT AND PROPER REQUIREMENTS

Fit and Proper Policy

The Company has a 'Fit and Proper Policy' (the 'Policy') which has been approved by the Board and is regularly reviewed with the last review having taken place in 2019 and approved by the Board Risk Committee in September 2019.

The purpose of this Policy is to formally set out the relevant policies and procedures to ensure that the members of the administrative, management or supervisory body collectively in the Company possess both the Fitness; appropriate qualifications, experience and knowledge about:

- a) insurance and financial markets;
- b) business strategy and business model;
- c) system of governance;
- d) financial and actuarial analysis; and
- e) regulatory framework and requirements.

Relevant to their role; and Probity; honesty, ethical behaviour, financially sound and behaves with integrity; to effectively carry out their role.

It is the initial responsibility of ALPI dac's Human Resource function to determine if a role profile falls within the scope of the Fit and Proper Policy which is automatically applied to all employees in Control Functions (CFs) including Pre-Approval Control Functions (PCFs) as defined in the Central Bank Reform Act 2010 (Sections 20 and 22). PCF's also require the pre-approval of the Central Bank of Ireland prior to taking up their positions.

Under the Policy an assessment must be completed before a person becomes the holder of a PCF or CF role. ALPI dac makes all reasonable inquiries to obtain information, including collecting sensitive information that it believes may be relevant to an assessment of whether the person is fit and proper to hold the position the person is proposed to be appointed to. This includes, but is not limited to, verification of educational or professional qualifications, reference checks and a review of available public information in relation to directorships, judgements, bankruptcy etc.

The Policy also requires that all PCF and CF position holders must be in a position to comply with the Standards as set out in the Policy on an ongoing basis and a Fit & Proper self-declaration is completed by all PCF / CF individuals on an at least annual basis.

B.3. RISK MANAGEMENT SYSTEM INCLUDING THE OWN RISK AND SOLVENCY ASSESSMENT

B.3.1 Overall risk management system: strategies, processes and reporting procedures

The Risk Management Framework (RMF) forms an integral part of the management and Board processes and decision-making framework across the Company. The key elements of this framework comprise risk appetite (including risk preferences and risk tolerances); risk governance, including risk policies and business standards; and the processes used to identify, measure, monitor and report risks, including the use of risk models and stress and scenario testing.

To promote a consistent and rigorous approach to risk management across all parts of the business, there is a set of risk policies and business standards which set out the requirements for risk strategy, appetite, and minimum requirements for the Company's operations.

For the purposes of risk identification and measurement, risks are usually grouped by risk type: credit, market, liquidity, underwriting and operational risk. Risks falling within these types may affect a number of metrics including those relating to balance sheet strength, liquidity and profit. They may also affect the performance of the products delivered to customers and the service to customers and distributors, which can be categorised as risks to the brand and reputation or as conduct risk.

A regular top-down risk assessment and reporting process is facilitated by the Risk Management function. This includes the consideration of emerging risks and is supported by deeper thematic reviews. This, together with the risk and control self-assessment (RCSA) process, are the main processes used to Identify Measure, Manage, Monitor, Report (IMMMR) risks. They are run separately but are complementary. The RCSA process is run by the first line, with challenge by the Risk Management function. It focuses on

operational risks, which are recorded on 'iCARE', the Company's risk management system.

Risk models are an important tool in the measurement of risks and are used to support the monitoring of the risk profile and in the consideration of the risk management actions available. A range of stress tests are carried out (where one risk factor, such as interest rates, is assumed to vary) and scenario tests (where combinations of risk factors are assumed to vary) to evaluate their impact on the business and the management actions available to respond to the conditions envisaged.

The Risk Management function is accountable for quantitative and qualitative oversight and challenge of the IMMMR process and for developing the RMF. Internal Audit provides an independent assessment of the risk framework and internal control processes.

Board oversight of risk and risk management across the Company is maintained on a regular basis through the Board Risk Committee.

The Board has overall responsibility for determining risk appetite, which is an expression of the risk the business is willing to take. Risk appetites are set for solvency and liquidity. The position against risk appetite is monitored and reported to the Board Risk Committee on a regular basis.

It is recognised that it is important to have an appropriate risk culture ("tone from the top"). An appropriate culture includes the effective management of exposures, adequate resourcing, effective communication, malpractice reporting, a business ethics code that is annually signed up to by employees, and a commitment to integrity, ethical behaviour and compliance.

A risk and control goal is set for senior management as part of the annual bonus plan to help drive and reward effective risk management and a robust control environment. This is assessed on an annual basis by the Risk Management function.

B.3.2 The 'three lines of defence model', and roles and responsibilities of key functions

Roles and responsibilities for risk management are based around the 'three lines of defence model' where employees are involved in the management and mitigation of risk. The roles of the three lines of defence each contribute to embedded risk management.

The first line: management monitoring

Management are responsible for the application of the RMF, for implementing and monitoring the operation of the system of internal control and for providing assurance to the Board Risk Committee (BRC), Operational Risk and Conduct Committee (ORCC), Asset and Liability Committee (ALCO) and Audit Committees, and the Board.

The second line: Risk Management, Compliance and Actuarial functions

The Risk Management function is accountable for developing the RMF and for the quantitative and qualitative oversight and challenge of the IMMMR process. As the business responds to changing market conditions and customer needs, the Risk Management function regularly monitors the appropriateness of the Company's risk policies and the RMF to ensure they remain up to date.

The Compliance function supports and advises the business on the identification, measurement and management of its regulatory, financial crime and conduct risks. It is also accountable for monitoring and reporting on the compliance risk profile.

The Actuarial function is accountable for actuarial methodology, reporting to the relevant governing body on the adequacy of reserves and capital requirements, as well as underwriting and reinsurance arrangements.

Refer to sections B.4. and B.6 for further details on the roles, responsibilities, authority, resources, independence and reporting lines of the Compliance and Actuarial functions respectively, and how their independence is ensured.

The third line: Internal Audit

This function provides independent and objective assessment on the robustness of the RMF and the appropriateness and effectiveness of internal control to the Audit, Conduct, Risk and Investment Committees, and the Board.

Refer to section B.5 of this report for details on the roles, responsibilities, authority, resources, independence and reporting lines of the Internal Audit Function.

B.3.3 Risk Management function

The Risk Management function is responsible for the design and implementation of the risk management system. The Risk Management function reports to the board on material risks identified, together with any other specific areas of risk requested by the board, and assists the board and management in the effective operation of the risk management system through the provision of specialist analysis and quality reviews, an aggregated view of the risk profile, and an assessment of the key risks associated with the business's strategy, major projects, strategic investments and other key decisions.

The Risk Management function has authority to review all areas of the business and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work. The scope of Risk's activities extends to all legal entities, joint ventures, partnerships, outsourcing and reinsurance arrangements.

The Risk Management function operates as part of the Global Risk function, which includes the Actuarial and Compliance functions as well as Risk Management. Further information on the Compliance and Actuarial functions is set out in sections B.4 and B.6 respectively.

B.3.4 Integration of risk management into the decision making processes

All key management level decisions must have the support of the Risk Management function before proceeding and the Chief Risk Officer has the power of veto.

B.3.5 Risk management system: Own risk and solvency assessment (ORSA)

The ORSA Report is the outcome of the combined processes and procedures (collectively ORSA processes) in place to manage and assess the risk and solvency position of the Company. The goal of the ORSA process is to provide a continuous and forward-looking assessment of the short-term and long-term risks that the Company faces, or may face, ensuring that solvency requirements are met at all times.

The ORSA processes comprise a number of elements of the RMF which are embedded in the business through the requirements of supporting risk policies and business standards around strategy, planning, capital management, stress and scenario testing and use of Solvency II capital in decision making.

In combination, these elements create a holistic overview of the elements of risk that may impact the Company, and which should be taken into account by management in day-to-day decision-making, in particular through the use of Solvency II capital, and ensures risk and capital management are connected.

The ORSA Report articulates the Board's formal view of the capital the Company needs to hold, given the risks currently faced by the business and how these might evolve over time, in line with delivery of the business strategy. It summarises a high level description of the key components of the underlying ORSA processes and the key outcomes from these processes.

Consistent with the three lines of defence model, first-line management is responsible for the implementation of the majority of the underlying ORSA processes.

The output from the ORSA processes is reported to the Board and the Risk Committee regularly during the year. The ORSA Report is produced annually, usually following the Board's approval of the Company's three-year Business Plan. The Chief Risk Officer is responsible for producing the ORSA Report which is reviewed and approved by the Risk Committee and the Board.

The Board has approved that for the purpose of ORSA, capital resources and requirements are measured on the basis of Solvency II requirements for determining Solvency II Own Funds and SCR.

Solvency II capital, (as a risk-based capital measure), is embedded at the heart of the Company's risk and capital evaluation and is used as a key input to a wide range of business and strategic decisions. Solvency II capital is calculated using the Standard Formula.

The RMF, supported by risk policies and business standards, sets out the areas where businesses are expected to use Solvency II capital management information as part of their decision-making and risk management processes. This ensures that requirements to



use Solvency II capital are embedded within the instructions of how the relevant processes (for example asset liability management or strategy and planning) are to be performed.

B.4. INTERNAL CONTROL SYSTEM

Internal Control Statement

The Company has a robust risk oversight process in place. The Operational Risk and Control Management (ORCM) framework facilitates the development of robust and reliable internal controls and ensures the following:

- Consistent identification, measurement, management, monitoring and reporting of all key risks;
- The controls are proportionate to manage risks, are adequately documented, maintained and reviewed;
- Documentation of agreed 'route to green' (RTG) plans for risks out of tolerance;
- The risk and control environment is monitored and reported upon regularly.

The Operational Risk & Conduct Committee has defined terms of reference and appropriate membership, with proceedings adequately recorded and actions followed up.

The Company's organisational structure includes the operation of a three lines of defence model, segregation of duties, a delegated authorities framework, and the consideration of risk management and control responsibilities when setting objectives for and reviewing the performance of all staff.

Compliance Function

The Company has a Compliance Function which is established pursuant to Solvency II and the Compliance Policy of the Company. During 2018, due to the increasing focus on Financial Crime matters the Compliance Function was split into a Compliance Team and a Financial Crime team. The Compliance Team is led by the Head of Compliance with a team of three staff members and the Financial Crime team is led by the Head of Financial Crime with a team of four staff members. A Regulatory Risk Monitoring team exists within the risk function which provides monitoring activities to the Company.

The primary purpose of the Compliance function is to assess and manage the business's exposure to regulatory risk. The Compliance function is an integral part of the RMF and constitutes a key part of corporate governance. The function is a critical contributor to the safe and sound operation of the business and underpins the achievement of strategic and business goals.

Three key processes comprise the Company's compliance activity:

- Conduct regulatory risk management (including monitoring regulatory developments), performed by the Compliance function (including the Financial Crime Team) and including activities such as;
 - Setting conduct and financial crime policy framework;
 - Provide advice, support, guidance and challenge on conduct and financial crime risk; and,
 - Manage conduct and financial crime regulatory engagement.
- Prudential regulatory risk management (including monitoring regulatory developments), performed by the Risk Management function and including activities such as;
 - Provide advice, support, guidance and challenge on prudential regulatory risk; and,
 - Manage prudential regulatory engagement.
- Legal developments monitoring is performed by the Legal and Company Secretarial functions.

The Compliance function (including the Financial Crime and Monitoring Teams) has authority to review all areas of the business and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work.

The Company has a Compliance Policy/Charter which is reviewed regularly by the Board and sets out, inter alia: the interacting responsibilities and reporting duties of the Compliance function and the Company. In addition, the Board Risk Committee will approve the Compliance Plan for each calendar year and thereafter assess the performance of the function in achieving the plan, or otherwise.

B.5. INTERNAL AUDIT FUNCTION

The role of the Internal Audit function is defined in ALPI dac's Internal Audit Charter. The Charter sets out the purpose, activities, scope and responsibilities of the Internal Audit function within ALPI dac and the arrangements for the management of the function, including ensuring its independence from 1st and 2nd line management of the Group.

The scope of Internal Audit (IA) assurance activities includes:

- Assessing and reporting (to group and ALPI DAC audit, risk and governance committees and to management as appropriate) on the effectiveness of the design and operation of the framework of controls which enable risk to be assessed and managed.
- Assessing and reporting (to group and ALPI DAC audit, risk and governance committees and executive management as appropriate) on the effectiveness of management actions to address deficiencies in the framework of controls and risks that are out of tolerance.
- Assessing key corporate events such as acquisitions/divestments and outsourcing decisions to determine and report on whether key risks are being adequately addressed. IA may also assess relevant post-mortem or "lessons learned" analysis following significant adverse events at the organisation or in the industry.

IA also:

- Undertakes designated advisory projects for management, provided that they do not threaten IA's actual or perceived independence from management.
- Investigates and reports on cases of suspected or alleged instances of internal and non-customer malpractice or financial crime.
- Manages the relationship with Aviva's independent malpractice reporting service, Speak Up, in accordance with the Speak Up Charter.

IA is responsible for performing these activities efficiently and effectively, but it is not responsible for setting risk appetite or for the effectiveness of the framework of controls.

The Audit Committee receives quarterly control reports from Internal Audit and challenges management on the actions being taken to evidence that the governance, risk management and controls remain effective; whether the overall level of operational risk remains within appetite and if not, to challenge Management to address this within an acceptable timeframe.

Internal Audit must be independent from management at all times in order to be effective in performing its activities. The Internal Audit Function maintains its independence and objectivity by having a direct reporting line to the Chair of ALPI DAC's Audit Committee and a functional reporting line to the Audit Director Europe of Aviva Group who reports to the Group Chief Audit Officer. The Group Chief Audit Officer reports to the Chairman of Aviva PLC's Audit Committee and has a functional reporting line to the Group Chief Executive Officer.

The Chair of the ALPI DAC Audit Committee is responsible for recommending the appointment or removal of the Head of Internal Audit to the Board and participating, jointly with the Group Chief Audit Officer or designee, in the determination of the objectives of the Head of Internal Audit and the evaluation of their levels of achievement, including consultation with the Chief Executive Officer.

Internal auditors previously working in ALPI dac, but outside Internal Audit, will not perform or manage reviews in the business area for which they were previously responsible for a period of at least one year after the end of their role within the business. This excludes performing or managing reviews in similar business areas in other legal entities or operating units for which they were not previously responsible. Internal auditors on rotation from a business unit will not perform or manage reviews in the business area for which they were previously responsible.

Internal Audit provides the Audit Committee with an annual confirmation of its independence, supported by an independence declaration form signed by all members of Internal Audit staff.

B.6. ACTUARIAL FUNCTION

Role & Responsibilities

The Head of Actuarial Function is appointed by the Board. The Actuarial Function is accountable for actuarial methodology, reporting to the relevant governing body on the adequacy of reserves and capital requirements, and on the adequacy of underwriting and reinsurance arrangements.

The independence of the Actuarial Function is derived through its reporting line being direct to the CEO and Board, and therefore being independent of financial functions. In co-ordinating the calculation of technical provisions, the Actuarial Function works closely with the Finance Function to agree a number of principles in respect of the calculation of technical provisions (best estimate liabilities) and capital requirements. Nevertheless to ensure independence it does not participate in their calculation. The Actuarial Function reviews and challenges the output from the Finance Function.

The Head of Actuarial Function's reporting line is direct to the CEO. The Actuarial Function works closely with Risk Management and elements of the Compliance Function to form an effective second line of defence. The Head of Actuarial Function is a member of the Executive Committee and attends the Board, Risk, Audit and Finance committees as necessary.

Authority and Resources of the Actuarial Function

The Actuarial Function has authority to review all areas of the business and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work. All persons employed by the Actuarial Function in a defined actuarial role, are subject to Aviva's Fit and Proper minimum requirements to ensure they have the required skills and knowledge to comply with their role and responsibilities.

B.7. OUTSOURCING

The Board has approved an Outsourcing Policy which must be followed in circumstances where the Company seeks to outsource any activities which, as a Life Assurance entity it might otherwise be expected to carry out itself, but where the Company has identified benefits in outsourcing that activity. This Policy is cognisant of the Solvency II requirements when outsourcing such activities and seeks to comply with all requirements.

The Policy sets out the requirements which must be followed prior to outsourcing such activities and the ongoing monitoring of these activities. This is to ensure that any Outsourcing activity is undertaken in accordance with a structured control process with appropriate and ongoing accountability and responsibility within the Company as the regulated entity. Close management oversight and monitoring of Outsourced relationships is required under the policy. The Policy is also in compliance with local laws, regulations and best practice.

The Company outsources a number of critical Important operational functions as defined by applicable Solvency II Regulations, CBI guidelines and the Company's Internal Supplier Classification tool. These mainly relate to Investment Management of own funds and Unit linked Policyholder funds, Custodian Services, Administration services of middle & back end office administration services, the provision of printing and mailing services for policyholder communications, and, as a result of Brexit, the administration of an Overseas Life Assurance Book (OLAB) book of Business which is a closed book. Being part of a large insurance group there are Intracompany outsourcing arrangements with Aviva Central Services that provide a number of group services, e.g. Finance, Actuarial & IT Infrastructure, all of which are subject to the same monitoring and oversight. All such providers are based in the EU and India but primarily in Ireland and the UK. The reason for outsourcing the above functions include utilising external third party specific skills , leveraging knowledge & skill internally within the group and cost synergies.

An Outsourcing oversight committee is in place and meets regularly throughout the year (minimum 8 times), the focus of the ALPI dac Outsourcing Committee is to act on behalf of the ALPI dac ExCo to ensure that ALPI dac has in place appropriate outsourcing governance and oversight implemented through an Outsourcing Risk Management Framework and that the ALPI dac Outsourcing Strategy is aligned to the overall ALPI dac Business Strategy.

In choosing each of the service providers, the Company has satisfied itself that each provider has the capacity and authorisation required by law to deliver the required functions or activities satisfactorily, in accordance with its Outsourcing Policy.

B.8. ANY OTHER INFORMATION

The Company's system of governance is adequate for the nature, scale and complexity of the risks inherent in its business. The system of governance is assessed periodically and policies are reviewed regularly.

The Company's overarching risk management and internal control system is responding well to the challenges of the Covid-19 outbreak and remains intact. Work is in progress in capturing some aspects of change to the control environment to make allowances for the operational constraints. Any moderations are being closely monitored and subject to appropriate governance.

Government travel restrictions and social distancing measures in our major markets have required us to implement contingency plans and changes to some of our operational processes to ensure continued uninterrupted service to our customers, while minimising the impact on the quality of service provided. These plans involve most of our staff being able to work from home, including most of our customer contact staff. The changes to operational processes that have been implemented have been designed to ensure customer service, data protection and staff well-being risks are at a level accepted by Management.

C. RISK PROFILE

This section identifies the different risks to which the Company is exposed, the measures used to assess these risks, the techniques used to mitigate these risks and the processes to monitor the risk exposures. The appetite for different risks is set by our Board.

Risk assessment is carried out regularly. It is identified using management information, experience and trend analysis, information from the Risk Management function and risk committee and any external data available.

The Company holds capital in order to ensure that it can meet its obligations across a wide range of risk scenarios. The main basis used by the Company to determine the amount of capital to hold is the Solvency II Solvency Capital Requirement (SCR). This determines the capital needed if a 1 in 200 year loss event occurs. The Company has adopted the Standard Formula approach to determine the capital required based on its risk profile. An assessment has been carried out by the Company to confirm that its use of the Standard Formula is appropriate. The Standard Formula provides information on stresses to each of the risk types. Additional scenario based stresses are carried out as part of the ORSA. Based on these results, the company is satisfied that the Standard Formula is appropriate.

The Company notes that the vast majority of its Best Estimate Liabilities (BEL) relate to either unit-linked business or business within with-profits funds where the BEL reflects the value of the assets in the funds.

Scenario and stress testing are used in addition to the SCR to determine the target level of capitalisation.

The use of capital alone is not sufficient to mitigate risk. A variety of risk mitigation techniques are used in addition to reduce and manage risk, e.g. reinsurance, operational controls. These techniques are described in more detail below.

The risk mitigation techniques are constantly monitored and reviewed to ensure that they remain effective.

As at Q4 2019, the majority of non-linked assets held were invested in Sovereign Bonds, Corporate Bonds and Cash which produce regular income to meet outgoings. The Company considers these assets to be highly liquid and of an appropriate duration. Therefore, liquidity is not considered to be a key risk. Where appropriate the Company has used Reinsurance to mitigate against risk. All remaining risks are present mainly for the benefit of policyholders and are acceptable from the Company's point of view.

C.1. UNDERWRITING RISK

DESCRIPTION


Underwriting risk is the risk of loss due to unexpected variation in the amount or timing of claims, premiums or expenses on the policies that we have underwritten. Aviva Life & Pensions Ireland dac currently writes life insurance business which results in material exposures to the following risks:


- Mortality the risk of loss due to adverse deviations in the timing and amounts of claims due to higher than expected mortality rates
- Longevity the risk of loss due adverse deviations in the timing and amounts of claims due to lower than expected mortality rates
- Morbidity the risk of loss due to adverse deviations in the timing and amount of claims due to higher than expected claim rates or lower than expected recovery rates
- Expense the risk of loss due to adverse deviations in the timing and amount of expenses incurred by the business
- Lapse the risk of loss due to policies surrendering earlier than expected
- Catastrophe the risk of losses in the event of a catastrophic event, e.g. a pandemic
- Revision the risk of adverse variation of an annuity's amount as a result of an unanticipated revision of the claims process.

Insurance products expose ALPI DAC to one or more of these risks; we use our experience to identify, measure, manage and mitigate these risks.

The risks above have been quantified using the Standard Formula. The charts below show the relative significance of each component on the life and health underwriting risks as at 31st December 2019.







RISK MANAGEMENT

Risk Committee

See Section B.3 for details about this committee.

Own Risk and Solvency Assessment (ORSA)

The ORSA (refer to section B.3.4.) describes the processes and procedures used by ALPI DAC to identify, measure, monitor, manage and report the risks being faced and to determine the own funds necessary to ensure that overall solvency needs are met at all times. This is required as part of Solvency II.

As part of this process we identify and measure all risks, both qualitatively and quantitatively. Processes are devised to monitor and manage these risks. Stress tests are also carried out which will enable us to determine the level of risk we are exposed to. We also carry out projections to ensure that we meet solvency requirements in the future.

Reinsurance

We use reinsurance to reduce our exposure to the risk of adverse claims experience. Our reinsurance limits are set by our Risk Committee based on our risk appetite. We regularly review our reinsurance strategy and make changes when necessary.

Underwriting

Our underwriting process allows us to assess the risks before we write a policy, and also at claim stage before we pay a claim.

Product Pricing

When developing products risk is taken into consideration, the acceptable level of risk is determined in advance by our Risk Committee. The experience of our products is monitored and compared to expectations and this information is used in the pricing of new products or in premium reviews.

We also monitor sales to ensure the volume and mix of new business are in line with expectations.

Risk Concentration

Almost all of our risk is insured in Ireland, with European life assurance business being 100% reinsured. This can lead to a concentration risk. Similarly, we face concentration risk from our group risk schemes. Some of this risk is mitigated through reinsurance.

C.2. MARKET RISK

DESCRIPTION

Market risk is the risk of loss arising due to changes in the market price of assets. The main areas of market risk are as follows:

- Equity risk the risk of loss arising from a fall in equity values. The Company is primarily exposed to equity risk through future management charges on the unit linked funds and equity holdings in the defined benefit pension scheme but may have exposure in respect of any direct equity holdings in non-linked funds. The equity risk on unit linked funds is accepted by the Company on behalf of its policyholders.
- Property risk the risk of loss arising from a fall in property values, either direct or indirect holdings. The Company is exposed to property risk through in respect of future management charges on the unit linked funds. In addition, the Company is exposed to property risk for any non-linked property holdings. The property risk on unit linked funds is accepted by the Company on behalf of its policyholders.
- Currency risk the risk resulting from the sensitivity of the values of assets and liabilities to changes in the level or volatility of currency exchange rates. The Company is exposed to currency risk through non-euro denominated non-linked and unit linked asset holdings. In addition, the Company is exposed to currency risk in respect of future management charges on the unit linked funds. The currency risk on unit linked assets is accepted by the Company on behalf of its policyholders.
- Spread risk the risk of loss or adverse change in the value of assets and liabilities, resulting from fluctuations in the credit standing of issuers of securities. The Company is exposed to spread risk through non-linked corporate bond holdings.
- Interest rate risk the impact of changes in interest rates on Own Funds. It relates to any mismatch of the durations of the




assets and liabilities. It also includes any duration mismatch identified within the Company defined benefit pension scheme. Interest rate risk on unit linked funds is accepted by the Company on behalf of its policyholders.

• Concentration risk – this arises on any single exposure or group of exposures with the same counterparty. Government bonds are not subject to concentration risk. Given the Company's large holding of government bonds, its concentration risk is zero.

The above risks have been quantified using the Standard Formula.

The chart below shows the relative significance of each risk at 31 December 2019.



RISK MANAGEMENT

ORSA

As part of the ORSA process market risks are assessed. In addition, stress tests are carried out which will enable us to determine the level of risk we are exposed to. This can help us to determine the best mitigation methods.

Monitoring

Our Asset and Liability Committee regularly monitors market risk to ensure that the level or risk is within our risk limits. They can identify trends and deviations over time and take action to reduce the level of risk.

Asset liability matching

All unit linked liabilities are matched with appropriate assets. Annuities are matched by bonds of appropriate nature and duration.

C.3. CREDIT RISK

DESCRIPTION

Credit risk is the risk of loss from a counterparty's unexpected inability to meet its contractual obligations or deterioration in credit standing. Our main source of counterparty risk is from our investments, namely government bonds, corporate bonds and bank deposits. We are also exposed to counterparty risk through our reinsurance arrangements. Counterparty default risk has been quantified using the Standard Formula.

The Company's counterparty exposure increased during the year due to the Part VII transfer, which increased the level of reinsurance recoverables and investment exposures. In particular, the 100% reinsurance of European life assurance business to UKLAP represents the Company's largest counterparty exposure.

RISK MANAGEMENT

Investments

Investment in government bonds is diversified across the Eurozone. We invest in a range of sovereigns that are of sufficient credit quality. Our Asset and Liability Committee identifies these counterparties. For bank deposits we have a range of approved institutions. The investments are continually monitored to ensure that we are operating within our risk limits.

Reinsurance

We only interact with reinsurers that have a satisfactory credit rating. We regularly monitor the credit rating of our reinsurers. Where possible we would enter into a collateral agreement in order to mitigate some of the risk. We also avoid large exposures to a single reinsurer where possible.

ORSA

As part of the ORSA process stress tests are carried out which will enable us to determine the level of risk we are exposed to. This can help us to determine the best mitigation methods.

Risk concentration

Our main sources of risk concentration arise from our investments in bonds and cash, and also our reinsurance arrangements. We try where possible to diversify to ensure that we are not overly exposed to any particular counterparty.

C.4. LIQUIDITY RISK

DESCRIPTION

Liquidity risk is the risk of loss due to the inability to meet a financial obligation to a policyholder or other creditor as it falls due. This can happen even when a company meets all its solvency requirements. Liquidity risk is monitored regularly to ensure that the level of risk remains acceptable. We do not expect liquidity to be a key risk.

RISK MANAGEMENT

Investments

As at 31 December 2019 the majority of the non-linked assets are invested in sovereign bonds and cash, these produce regular income to meet outgoings. These are highly liquid assets and of an appropriate duration. Adequate funds are held in cash for day to day expenses; these are reviewed regularly.

Unexpected claims

This can result from higher than expected claims or policy surrenders. This is mitigated by investing in high quality liquid assets that can be realised over a short period. Some policy conditions allow us to defer claim payments in the case of illiquid underlying assets.

In January 2020, a 6-month moratorium on redemptions was placed on the Friends First Irish Commercial Property Fund and Aviva Irish Property Fund. This action is taken to protect the long term interest of the funds and reduces the exposure to forced sale of assets.

Stress testing

Stress testing is carried out to ensure that we have sufficient liquidity in extreme circumstances. This will enable us to reduce the liquidity risk.

Risk concentration

As all of our insured risk is in Ireland, the concentration risk is that of excessive claims, which could lead to liquidity problems. Stress testing should highlight this risk.



Expected profit included in future premiums

We are required by the regulations to state the expected profit included in future premiums. The total amount of expected profit included in future premiums (EPIFP) is set out in the table below.

		€ 1,000
	2019	2018
EPIFP Life insurance	165,374	92,037
EPIFP % Tier 1 Eligible Own Funds	23%	38%

The EPIFP increased by over €73m in 2019, due to the addition of further regular premium business through the Part VII transfer.

C.5. OPERATIONAL RISK

DESCRIPTION

Operational risk is the risk of loss caused by inadequate or failed internal processes, people and systems or from external events. It can also arise in a changing regulatory environment if we fail to demonstrate compliance in the event of a change.

Operational risk has been quantified using the Standard Formula. We accept a certain amount of operational risk as part of our business model.

RISK MANAGEMENT

Business Continuity Plan (BCP)

The Company has a BCP in place. The BCP includes an external site where the Company can relocate in the event that the office or computer systems become unusable for a period. The testing of the BCP indicates that the Company could bring its systems live at the external sites in a matter of hours.

Cyber risk security measures

The Company's IT department has in place an extensive range of security measures to protect the integrity of the system and the security of the data. It also engages with the business to ensure awareness of the threats that exist. This includes conducting education sessions with all staff. IT engage with external experts to benchmark its security posture against best practice.

Regulatory changes

Regulations are monitored by the relevant departments in the company. Any changes will be reviewed and procedures put in place to ensure that we continue to demonstrate compliance.

ORSA

As part of the ORSA process operational risks are assessed. In addition, stress tests are carried out which will enable us to determine the level of risk we are exposed to. This can help us to determine the best mitigation methods.

Risk concentration

All of our administration is carried out in two offices in Dublin City Centre and South County Dublin, this represents a concentration risk. This has been significantly mitigated with our BCP mentioned above.

Other Operational risks are likely to result in a financial loss. The Company believes it has satisfactory processes and controls to address and manage its Operational Risk.

C.6. OTHER MATERIAL RISKS

There is no other material information relevant to the risk profile of the Company.

C.7. ANY OTHER INFORMATION

C.7.1. SENSITIVITIES TO KEY FACTORS

This section sets out indicative sensitivities to a range of key factors. For each sensitivity we show the impact of a change in that single factor while leaving all other factors unchanged. The factors examined are as follows:

- Interest rates The impact of a 0.5% increase/decrease in interest rates on the value of both assets and liabilities.
- Expenses The impact of a permanent 5% increase in <u>all</u> expenses <u>and</u> a 0.5% increase in expense inflation.
- Lapses The impact of a permanent 10% increase in lapses.
- Mortality The impact of a permanent 5% increase in the mortality rates (excluding annuitants).
- Morbidity The impact of a permanent 5% increase in morbidity rates.
- Annuitant Mortality The impact of a permanent 5% decrease in the mortality rate of people to whom we pay annuities.
- Equity Values The impact of a 10% decrease in equity values on both assets and liabilities.
- Property Values The impact of a 25% decrease in property values on both assets and liabilities.

The results of these sensitivities are as follows:

Base Solvency Coverage	150%
Sensitivity description	Impact on Solvency
0.5% increase in interest rates	+3%
0.5% decrease in interest rates	-4%
Increase of 5% in expenses & 0.5% in inflation	-8%
10% increase in lapses	-3%
5% increase in mortality rates	-2%
5% increase in morbidity rates & 3% reduction in recovery rates	-3%
5% decrease in annuitant mortality rates	-7%
10% decrease in equity values	-4%
25% decrease in property values	-2%

C.7.2. PRUDENT PERSON PRINCIPLE

The Company ensures that its assets are invested in accordance with the Prudent Person Principle as set out in Article 132 (Directive 2009/138/EC) through the collective application of its risk policies and business standards. These ensure that the Company invests in assets whose risks it can properly identify, measure, monitor, manage, control and report, and appropriately take into account in the assessment of its overall solvency needs having regard to the term and nature of its liabilities. The Company's Asset Liability Management Business Standard and certain provisions of the Investment Management Business Standard contain mandatory requirements to ensure that the Company develops its own set of key risk indicators and takes into account the risks associated with its investments without relying only on the risk being adequately captured by the capital requirements. Risk appetites by risk type are also set and monitored by the Company. Other business standards set requirements for the quality of investment assets (including setting risk limits to control the market and credit risk within a portfolio), matching of assets to liabilities, diversification of invested assets and use of derivatives.

C.7.3. OTHER INFORMATION

The current process for monitoring the risks, the risk-mitigation techniques in place and the material concentrations of risk to which the business is exposed as a result of COVID 19 for each of the Company's key risk types are as follows:

Underwriting risk

The principal Life underwriting risks impacted by the Covid-19 pandemic are mortality and morbidity risks, where our greatest geographic exposure is to Ireland. We have reinsurance in place to reduce our net exposure to potential losses. We have a high-level of quota share reinsurance in place on Individual Protection business, and for Group Life protection we have surplus reinsurance for individual claims and a lower-level of quota share reinsurance.

Underwriting procedures on Individual Life Protection products limit our exposure to cohorts of the population at highest risk of Covid-19 (i.e. the elderly and those with pre-existing conditions). While we have greater potential net exposure through Group Life Protection, we are taking pricing actions to limit our potential exposure from new business. We expect there to be some offset to increased protection claims as a result of Covid-19 from reserve releases on our annuity portfolio.

For Income Protection business, while we have some potential exposure to income protection claims arising from Covid-19, our policy terms typically include a deferment period after which benefits become payable to policyholders, and in most cases we expect the deferment period to be longer than the symptomatic period of Covid-19. This materially decreases our exposure.

Market risk

As a result of the financial market impact of Covid-19 we have taken a number of actions to reduce our exposure to equity, property and interest rate risk across all our markets. Actions include purchasing risk-mitigating derivative hedges, asset disposals and reallocations and reducing new business sales in certain markets and products.

Credit risk

As a result of the financial market impact of Covid-19 we have taken a number of actions to reduce our exposure to credit spread and counterparty default risk across all our markets. Actions include purchasing risk-mitigating derivative hedges, asset disposals and reallocation and reducing new business sales in certain markets and products.

Liquidity risk

We continue to closely monitor the Company's liquidity position on a daily basis. Liquidity remains very satisfactory as we have large cash holdings and also hold significant amounts of sovereign bonds which, at the moment, can be quickly converted to cash if required.

Operational risk

Covid-19 is resulting in some changes to operational processes that have been designed to ensure operational risks remain at an acceptable level. Further information is provided in Section B.

Asset management risk

In our asset management processes, our focus has been on our operational processes, including those around liquidity management within our funds, to ensure continued and uninterrupted service to our customers.

VALUATION FOR SOLVENCY PURPOSES D.

The table below gives an overview of the Company's assets and liabilities as at 31 December in the Balance Sheet for Solvency Il purposes in each of the last two years.

BAL	ANCE	SHEET

BALANCE SHEET		€ 1,000
ASSETS	2019	2018
Intangible Assets	0	0
Deferred tax assets	0	4,519
Property, Plant & Equipment held for own use	15,341	2,483
Investments (excl. index-linked and unit-linked funds)	4,196,689	1,460,367
Assets held for index-linked and unit-linked funds	8,419,747	2,942,216
Loans & mortgages	260,953	262
Reinsurance recoverables	1,860,928	382,643
Deposits to cedants	0	0
Insurance & intermediaries receivables	15,192	12,741
Reinsurance receivables	54,005	31,739
Receivables	60,866	4,057
Own shares	0	0
Cash and cash equivalents	83,883	49,924
Any other assets, not elsewhere shown	15,550	8,127
Total assets	14,983,155	4,899,078

BALANCE SHEET		€ 1,000
LIABILITIES	2019	2018
Technical provisions - non-life (excl. health)	0	0
Technical provisions - health (similar to non-life)	0	0
Technical provisions - health (similar to life)	271,010	209,399
Technical provisions - life (excl. health/ UL)	3,998,004	1,399,668
Technical provisions - unit-linked	9,210,642	2,883,363
Contingent liabilities	0	0
Provisions other than technical provisions	11,611	4,900
Pension benefit obligations	17,100	13,121
Deposits from reinsurers	0	0
Deferred tax liabilities	15,426	11,796
Derivatives	96,811	0
Debts owed to credit institutions	37,274	0
Financial liabilities other than debts owed to credit institutions	107,294	0
Insurance & intermediaries payables	207,658	88,992
Reinsurance payables	15,921	19,523
Payables	70,782	9,757
Subordinated liabilities	0	0
Any other liabilities, not elsewhere shown	19,857	10,302
Total liabilities	14,079,392	4,650,821
Excess of assets over liabilities	903,764	248,257

D.1. ASSETS

D.1.1. KEY ASSUMPTIONS AND METHODOLOGY FOR ASSET VALUATION

The asset values shown in the Solvency II balance sheet presented below are at "economic value". In general, the following definition is used for economic value:

- Assets shall be valued at the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction
- Liabilities shall be valued at the amount for which they could be transferred, or settled, between knowledgeable willing parties in an arm's length transaction

The following hierarchy is used by the Company to derive the economic value of an asset or liability, excluding the determination of the economic value of insurance liabilities.

- Level 1: The best evidence of the economic value is a quoted price in an active, deep, liquid and transparent market (mark-tomarket) for identical assets or identical liabilities. If quoted prices exist for similar assets or liabilities, the value of these should be used with an adjustment to reflect the prices.
- Level 2: If a quoted price does not exist or the market is deemed not to be active, the Company uses a valuation technique in determining the economic value. The Company will use a valuation technique which is commonly used in the industry (best practices) and will use market observable inputs (mark-to-model). Level 2 also comprises market quotes for products with similar characteristics.
- Level 3: If the key inputs of the valuation technique are not observable in the market or deemed not to be reliable, the Company will use its own inputs (if meeting the data quality requirements) as basis for the variables (mark-to-model). If a model is used to value a (financial) liability, the input parameters regarding the own credit standing may not be changed after the initial assessment.
- Level 4: In any other case, the Company will use "expert judgment" as basis for determining the economic value of assets or liabilities.

When measuring the economic value the Company will take into account any characteristic of the asset or liability including any restriction on the sale or use of the assets.

The table below shows the valuation hierarchy used to put a value on the Company's assets:

€r				€m
	Level 1	Level 2	Level 3	Total 2019
Debt securities		3,961	280	4241
Equity security investments	907		248	1155
Investment property			853	853
Loans			261	261
Other investments	4,523	562	6	5091
Investments in subsidiaries			1	1
Total	5,430	4,523	1,649	11,602

When possible the "look through" principle is used, in order to group all investments with similar risks together at the same balance sheet item. A look through procedure considers an investment at the most granular level of detail and distinguishes all risks involved. The Company looks for the economic substance of the (financial) instrument.

D.1.2. COMPARISON OF FINANCIAL STATEMENTS AND SOLVENCY II ASSETS

The Financial Statements of the company are prepared in accordance with International Financial Reporting Standards (IFRS) and the Companies Acts 2014.

When considering the definitions of economic value outlined above under Solvency II, it can be concluded that these closely match the current definitions as used within the International Financial Reporting Standards.

In the financial statements, the Company either measures or discloses the fair value of its investments. For most financial investments, since they are quoted on an active market, this is deemed to present a fair reflection for being an economic value. An active, deep, liquid and transparent ('ADLT') market for the asset or liability is a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. Transactions are taking place on a regular basis at arm's length.

D.2. TECHNICAL PROVISIONS

D.2.1. TECHNICAL PROVISIONS GENERAL

"Technical Provisions", as outlined on the Solvency II balance sheet, represents the measurement of the obligations stemming from insurance contracts the Company has written. These are contracts in which the Company assumes the insurance risk from another party - a policyholder. From the perspective of Solvency legislation an insurance contract is defined as selling business according to one of the defined lines of business by an authorised life or non-life insurer. The definition of the lines of business describes which risks are transferred from the policyholder to the insurer. The following lines of business are used:

- Health insurance (direct business) without options and guarantees;
- Insurance with profit participation;
- Index-linked and unit-linked life insurance without options and guarantees;
- Index-linked and unit-linked life insurance with options and guarantees; and
- Other life without options and guarantees.

The Technical Provisions are the sum of a Best Estimate Liability and a Risk Margin. Each of these is calculated separately and dealt with in turn below.

Best Estimate Liability

"Best Estimate Liabilities" are the best estimate of the value of the Company's obligations under the policies it has written.

Best Estimate Liabilities are based on the probability-weighted average of future cash-flows, taking account of the time value of money (expected present value of future cash-flows), using the relevant risk-free interest rate term structure. They are presented gross on the Balance Sheet (i.e. without deduction of the amounts recoverable from reinsurance contracts – see below).

Best Estimate Liabilities are calculated on a policy-by-policy basis.

Risk Margin

The "Risk Margin" reflects the extra premium another insurer would be expected to require to take over and meet the Company's insurance obligations.

The Risk Margin is calculated by determining the cost of providing an amount of Eligible Own Funds equal to the Solvency Capital Requirement (SCR) necessary to support the insurance obligations over their lifetime. The rate used to determine this cost is called the "Cost-of-Capital rate". It is set at 6% in the regulations.

Reinsurance Recoverables

Reinsurance reduces the Company's exposure to risks around variables such as mortality and longevity. "Reinsurance Recoverables" are netted off the Best Estimate Liabilities and Risk Margin. They are amounts:

- 1. the Company expects to recover from reinsurers based on recognised reinsurance contracts; or
- 2. already claimed from reinsurers based on previous or existing reinsurance contracts.

The valuation of the Reinsurance Recoverable consists of the following components:

- Best estimate of the recoverable of the reinsurance contract;
- Adjustment for timing differences; and
- Adjustment for the expected loss due to default of the counterparty.

For valuing the Reinsurance Recoverables, the Company applies a probability weighted average of the cash flows taking into consideration the probability of default and timing differences.

D.2.2. TECHNICAL PROVISIONS 2019

As described above, under Solvency II the technical provisions relating to insurance liabilities are made up of the Best Estimate Liability and the Risk Margin. The table below breaks down these components as at 31st December 2019, together with the impact of Reinsurance Recoverables:

€ 1,000				
	Health	Life	Unit-Linked	2019 Total
Best Estimate Liabilities	247,805	3,885,398	9,162,635	13,295,837
Risk Margin	23,206	112,607	48,007	183,819
Gross Technical provisions	271,010	3,998,004	9,210,642	13,479,656
Reinsurance Recoverables	84,251	787,186	989,491	1,860,928
Technical Provisions allowing for reinsurance Recoverables	186,759	3,210,818	8,221,151	11,618,729

D.2.3. KEY ASSUMPTIONS & METHODOLOGY IN DETERMINING THE TECHNICAL PROVISIONS

In order to value the technical provisions, as the future is uncertain assumptions are required for factors that are expected to vary. There are three main types of assumptions – demographic, economic and expense assumptions.

Demographic assumptions include when people are likely to die, how long people are likely to live and when are they likely to surrender their policies.

Economic assumptions include the discount rate, the rate of investment return and inflation.

Expense assumptions include policy maintenance expenses and investment expenses.

As well as assumptions, an actuarial model is also required to project future cashflows from each of the Company's insurance policies, including inflows such as premiums and outflows such as claims and expenses.

Please refer to section D.2.4. below for further information on the model and assumptions used.

BASIC RISK-FREE INTEREST RATE TERM STRUCTURE (RFR)

One of the economic assumptions required to determine the best estimate of the insurance liabilities is the relevant risk-free interest rate (RFR) as published by EIOPA. The RFR includes the currency-specific (Euro) element of the Volatility Adjustment (see below), however the country-specific element of the Volatility Adjustment for Ireland is zero. No other long-term guarantee assessment (LTGA) measures (Matching Adjustment or Transitional Measures) are used by the Company.

VOLATILITY ADJUSTMENT

The Volatility Adjustment (VA) is a reduction to technical provisions to reflect temporary distortions in spreads. It reduces the technical provisions by increasing the interest rate used to calculate the Best Estimate Liability. Volatility adjustments are prescribed by EIOPA on a currency and country basis.

The Company uses the VA when determining the best estimate of the insurance liabilities. The use of the VA is governed by a risk management assessment. The Central Bank of Ireland (CBI) determines whether the use of the VA is appropriate and it granted application of use of the VA for the Company in November 2019.

The Volatility Adjustment for the Euro at year end 2019 was determined by EIOPA as 0.07% (end of 2018 it was 0.24%).

TECHNICAL PROVISIONS EXCLUDING VOLATILITY ADJUSTMENT

The following table shows the impact of the Volatility Adjustment on the technical provisions.

	Including Volatility adjustment	Excluding Volatility adjustment	Impact Volatility Adjustment
Technical provisions minus recoverables from reinsurance	11,618,729	11,628,897	-10,168
Technical provisions – non-life (excluding health)	0	0	0
Technical provisions - health (similar to non-life)	0	0	0
Technical provisions - health (similar to life)	186,759	187,225	-466
Technical provisions – life (excluding health and index-linked and unit- linked)	3,210,818	3,220,393	-9,574
Technical provisions – index-linked and unit-linked	8,221,151	8,221,279	-128
Technical provisions – non-life (excluding health)	0	0	0

The Volatility Adjustment reduces net technical provisions by ≤ 10.2 m in total (≤ 0.5 m reduction for Health, ≤ 9.6 m reduction for Life and ≤ 0.1 m reduction for Unit-Linked).

D.2.4. UNCERTAINTY ASSOCIATED WITH THE TECHNICAL PROVISIONS

Valuation of the technical provisions requires the analysis of the underlying liabilities and the collection of qualitative and quantitative information. By its very nature, quantifying the level of uncertainty associated with the calculation of Technical Provisions is a difficult task. For the purposes of this report the Company have commented on this uncertainty under the following headings:

Assumptions

€ 1,000

The choice of assumptions is the main source of uncertainty. As the future is uncertain, actual experience will be different to what is assumed.

The assumptions are best-estimate, determined based on internal or external data collected by the Company and are consistent with information provided by the financial markets and generally available data on insurance and reinsurance risks. Assumptions are subject to second line review (refer to section B.3) and the assumptions setting process is longstanding and well established. Assumptions are reviewed quarterly to ensure they remain appropriate.

The technical provisions relating to unit linked insurance contracts are mainly determined by the value of assets in the unit linked funds. This, therefore, limits the amount of uncertainty for these types of policies.

Model

An appropriate valuation method has been selected to ensure that the nature and complexity of the insurance technical risks have been appropriately addressed. The selection of the appropriate method is based on expert judgement which has considered, among other things, the quality, quantity and reliability of the available data and analyse all important characteristics of the business.

The limitations of the method are known (some of the simplifications used are set out below).

- The Company has three profit sharing funds. The best estimate liabilities for these funds should include any distribution of surplus. At present the distribution of surplus of two of these funds is approximated based on the current market value of the funds' assets relative to the corresponding best estimate liabilities modelled. This leads to adjustments to modelled figures.
- Individual member data is not available to enable a valuation on a member by member basis for Group Risk. Best estimate liabilities are modelled by applying a loss ratio. This leads to adjustments to modelled figures.
- Some very old group pensions business remained on a system managed by Friend Provident (UK) after the Company became a separate entity. This data was never transferred to the Company core systems. Best Estimate Liabilities are measured using a roll up methodology.

Data

The stage of collecting and analysing the data requires compilation of appropriate data from internal operational systems and relevant external data. Data is subject to ongoing review by the first line (refer to section B.3). Furthermore the quality of policy data is subject to an annual data integrity check. This is to ensure completeness of data and also to check the validity of certain data items, namely:

- Policy Counts
- Annual Premiums
- Sum Assureds
- Secured Amounts (i.e. benefits on non-linked pension contracts)
- With Profit Bonus Amounts

D.2.5. COMPARISON OF FINANCIAL STATEMENTS AND SOLVENCY II LIABILITIES

The table below shows the differences between the financial statements and Solvency II liabilities, for each material line of business as at 31 December 2019:

€				
	Health	Life	Unit-Linked	2019 Total
Gross Financial Statements Liabilities	271,337	4,337,777	9,429,063	14,038,177
Adjustment for Solvency II	-327	-339,773	-218,421	-558,521
Technical Provisions	271,010	3,998,004	9,210,642	13,479,656
Gross BEL	247,805	3,885,398	9,162,635	13,295,837
Risk Margin	23,206	112,607	48,007	183,819

The main differences in the assumptions used for the financial statements and Solvency II are:

- In valuing the liabilities shown in the financial statements a valuation interest rate is used which is based on the yields of the assets held. Under Solvency II a risk-free yield (as prescribed by EIOPA) is used.
- Under Solvency II all liabilities are valued using best estimate assumptions. However, liabilities in the financial statements include margins to allow for adverse experience.
- The Solvency II liabilities include an allowance for the risk associated with them (the 'Risk Margin'). This is not included in the valuation of liabilities in the financial statements.
- Under Solvency II the discounted present value of all cashflows up to the contract boundary is included;. In the financial statements cashflows can continue beyond the contract boundaries used for solvency.
- For Unit-linked and With-Profits business, the inclusion of all future cashflows will reflect profits arising from these lines of business – asset management charges (in the case of unit-linked) and shareholder transfers (in the case of with-profits). These future profits are not recognised in the financial statements and the liabilities are effectively set equal to the assets.

For more information on the comparison of financial statement and Solvency II liabilities, see section E.1.4 below.

D.3. OTHER LIABILITIES

This section describes the following other liabilities which the Company has valued for Solvency II purposes, together with any differences in comparison with the financial statements:

- D.3.1. Provisions other than Technical provisions
- D.3.2. Contingent Liabilities
- D.3.3. Pension Benefit Obligations
- D.3.4. Payables
- D.3.5. Any Other Liabilities
- D.3.6. Deferred Taxes

D.3.1. PROVISIONS OTHER THAN TECHNICAL PROVISIONS

A provision is recognised when: (a) the Company has a present obligation (legal or constructive) as a result of a past event; (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and (c) a reliable estimate can be made of the amount of the obligation. Outlined below are the "Other Provisions" shown in the Solvency II balance sheet for year end 2018 and 2017. The figures have been discounted to their net present value of future cash flows.

		€ 1,000
	2019	2018
Other Provisions as at 31 December	11,611	4,900

During the year provision was made for an onerous lease in relation to an own use property.

D.3.2. CONTINGENT LIABILITIES



The Company assesses at each reference date whether "contingent liabilities" are to be recognised. Based on these assessments contingent liabilities are zero at the end of 2019 and also at prior year end, both for Solvency II purposes and in the financial statements.

D.3.3. PENSION BENEFIT OBLIGATIONS

Pensions Benefit Obligations are an employee benefit and are shown below. These relate to the difference between the liabilities and the assets in any pension plans the Company operates.

		€ 1,000
	2019	2018
Pension Benefit Obligations	17,100	13,121

The increase in the pension scheme obligations during the year related to market movements, primarily reductions in interest rates.

The Company presents other employee benefits (such as salaries, already declared bonuses) as part of the "other liabilities" on the Solvency II balance sheet (refer to D.3.5. below). Employee benefits are all obligations of the employer to employees or former employees.

The economic value of employee benefits is currently measured by reference to the value according to IAS 19R, which is included in the financial statements.

D.3.4. PAYABLES

Payables are measured in the Solvency II balance sheet as per the value presented in the financial statements. Payables due for a period less than three months are normally not discounted. However, if the contractual due period exceeds three months or the impact of not discounting is deemed to be material discount is applied. At the reference dates no discounting is applied.

		€ 1,000
	2019	2018
Payables from direct insurance	207,658	15,497
Payables on reinsurance	15,921	19,523
Claims accepted in relation to non in-force contracts	0	73,495
Creditors	0	0
Taxes	70,782	9,757
Total	294,362	118,272

D.3.5. ANY OTHER LIABILITIES

All other liability balance sheet entries are presented under this heading. This includes:

- Accruals not related to investments or investment property;
- Claims accepted not yet paid out in relation to contracts no longer in force;
- Other liabilities as presented as part of the Financial Statements.

Other liabilities are measured at their economic value. The Company considers the value as presented in the Financial Statements to be a fair representation of this economic value. Presented below is a breakdown of the "Any Other Liabilities" figure shown in the balance sheets.

		€ 1,000
	2019	2018
Accruals and deferred income	15,087	7,146
Other	4,770	3,156
Total	19,857	10,302

D.3.6. DEFERRED TAXES

Deferred tax is determined using the balance sheet liability method for temporary differences between the carrying amounts of assets and liabilities in the balance sheet and the amounts used for taxation purposes. The amount of deferred tax is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities using tax rates enacted or substantially enacted at reporting date. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the unused tax losses and credits can be utilised. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realised. The principles as defined by IAS 12 are applied. Deferred tax is recognised on valuation adjustments made between the financial statements and the Solvency II balance sheet. The Company assesses the recoverability of these adjustments, in conjunction with the changes in the deferred tax position.

Each addition to the deferred tax due to the valuation differences is calculated as that change in valuation multiplied by the corporation tax rate in Ireland of 12.5%.

Deferred tax entries in the Solvency II balance sheet are outlined below:

		€ 1,000
	2019	2018
Deferred tax assets	0	4,519
Deferred tax liabilities	-15,426	-11,796
Net deferred tax liability/asset	-15,426	-7,277

D.4. ALTERNATIVE METHODS FOR VALUATION

The Company does not use alternative valuation techniques.

D.5. ANY OTHER INFORMATION

D.5.1.IMPACT OF COVID-19 PANDEMIC

The COVID-19 pandemic has resulted in declines in global financial markets with a corresponding impact on the valuation of certain financial assets held at fair value within the Company's balance sheet. The pandemic has also resulted in an increase in volatility in financial markets, increasing the valuation uncertainty of assets and liabilities valued using an alternative method for valuation as described in section D.4. The Company has taken a number of actions to reduce exposure to market risk and credit risk and will continue to monitor its balance sheet exposure.

Technical provisions have been prepared based on conditions and best estimate assumptions at 31 December 2019 and have therefore not been adjusted for any impacts of COVID-19.

Life insurance technical provisions will be impacted through life protection products, as a result of increased mortality, and through income protection and critical illness products, as a result of increased morbidity. These impacts may be offset by a potential reduction in future annuity payments. Life insurance technical provisions will also be impacted by economic movements, although these are expected to be largely matched by movements in financial assets backing the liabilities.

We review the best-estimate assumptions used in the calculation of technical provisions on an ongoing basis and will update them accordingly for the expected impacts of COVID-19. However, given the rapidly evolving nature of the situation, it is not practicable at this stage to quantify the potential valuation impact of the pandemic and related financial market impacts, on the financial assets and technical provisions of the Company.

E. CAPITAL MANAGEMENT

E.1. OWN FUNDS

E.1.1. CAPITAL ADEQUACY POLICY

The capital adequacy of the Company is governed by the Capital Management Policy. The main principles of this policy are as follows:

- The statutory board is responsible for the solvency of the Company;
- The Company aims to keep an adequate level of capital;
- Solvency II is the leading capital regime for the Company;
- The Company and the Board are satisfied that the Standard Formula states an acceptable level of capital for the company. Therefore, the minimum level is defined as the level where the Company is capitalised at 100% SCR;
- The Board has expressed that the capital in the Company needs to be set at a level to ensure solvency cover exceeds the minimum level in many but not all circumstances.

Every calendar year, management of the Company produces a Business Plan for a prospective 3-year period, which is discussed in meetings of the Board in the second half of the year and approved before the end of the year. Under normal circumstances, as the Board wishes to create value, the Basic Own Funds will increase in the Business Plan period.

The Board will, as part of the Business Planning process, also carry out an assessment on the company's own view of the risks it is exposed to and contains forward looking projections for Basic Own Funds and Solvency Capital Requirement under certain stressed scenarios other than those projected in the Business Plan.

On the basis of these investigations the Board has a satisfactory view of how the SCR ratio might develop in the future, under central Business Plan assumptions as well as stressed scenarios.

The corporate governance mechanism around the calculation of the SCR ratio and potential declarations of dividends or requests for capital injections is set out in the Capital Management Policy. The Board will periodically, at least annually, assess the adequacy of this policy and make amendments where appropriate.

E.1.2. ELIGIBLE OWN FUNDS

Own funds represent the excess of the value of the assets over the value of the technical provisions plus other liabilities. The Company's own funds total €732m at 31 December 2019, reduced by €15m for a foreseeable dividend which was paid in February 2020. The table below shows a breakdown of the Company's own funds at both 31st December 2019 and 31 December 2018.

		€ 1,000
	2019	2018
Ordinary share capital (gross of own shares)	96,559	96,559
Share premium related to ordinary share capital	0	0
Surplus funds	199,560	0
Preference shares	0	0
Share premium related to preference shares	0	0
Reconciliation reserve	-77,578	148,699
Subordinated liabilities	0	0
An amount equal to the value of net deferred tax assets		
Other own fund items approved by the supervisory authority as basic own funds not specified above	498,372	0
Available own funds to meet SCR	716,912	245,258
Available own funds to meet MCR	716,912	245,258



Eligible own funds to meet SCR	716,912	245,258
Eligible own funds to meet MCR	716,912	245,258

There was a €486.7m increase in own funds during 2019.

ELIGIBLE OWN FUNDS

		e 1,000
	2019	2018
Tier 1 capital	716,912	245,258
Tier 2 capital	0	0
Tier 3 capital	0	0

Tier 1 capital

Tier 1 capital is of the highest quality and is the most loss absorbent and permanent form of capital. It includes ordinary share capital, non-cumulative preference shares and the reconciliation reserve.

Tier 2 capital

Tier 2 capital is likely to include cumulative preference shares and subordinated liabilities with a shorter duration.

Tier 3 capital

Tier 3 capital includes any other capital that does fall into the tier 1 and tier 2 categories, including net deferred tax asset. Tier 3 is the lowest quality capital. In 2019, as for 2018, the deferred tax liabilities were greater than the deferred tax assets, therefore the net deferred tax asset is zero.

Own funds must be eligible to cover the Solvency Capital Requirement and the Minimum Capital Requirement. The Solvency Capital Requirement must be backed by at least 50% tier 1 capital and no more than 15% tier 3 capital. The Minimum Capital Requirement must be backed by at least 80% tier 1 capital and no tier 3 capital.

As our capital is 100% tier 1, there are no issues with regards to capital eligibility.

Reconciliation reserve

		€ 1,000
	2019	2018
Excess of assets over liabilities	903,764	248,257
Own shares (held directly and indirectly)	0	0
Foreseeable dividends, distributions and charges	-15,000	0
Other basic own fund items	-794,490	- 96,559
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	-171,852	-3,000
Reconciliation reserve	-77,578	148,699

E.1.3. OWN FUND RESTRICTIONS/DEDUCTIONS

We do not calculate an SCR for the NM Defined Benefit pension scheme (this is a simplification in line with EIOPA guidance). As a result, this means the full amount of the NM Defined Benefit pension scheme surplus (≤ 2.6 m) is restricted and cannot be used to cover the SCR of the Company.

Furthermore, there is a restriction on the distributable surplus in the Irish With Profit Sub Fund (IWPSF) of €169.3m which is not included within Available Own Funds. This represents the Inherited Estate of the fund.

€ 1.000

E.1.4. BRIDGE OWN FUNDS FINANCIAL STATEMENTS - BALANCE SHEET

The Company's financial statements are completed on a different valuation basis to Solvency II. The table below shows the difference between the equity in the financial statements and the Solvency II own funds as at 31 December 2019 and December 2018.

		€ 1,000
	2019	2018
Equity attributable to Equity holder	703,189	162,937
Valuation differences		
- In respect of assets	-619,833	-221,637
- In respect of technical provisions	558,521	390,258
- In respect of other liabilities	261,887	-83,301
Total of valuation differences	200,575	85,320
Total SII excess of assets over liabilities	903,764	248,257

The differences are explained by differences in the valuation basis from financial statements to Solvency II and also due to some reclassification of items between lines.

E.1.5. SOLVENCY RATIO

Details of the Company's Solvency Ratio are shown in the table below, along with the impact of removing the volatility adjustment used.

There are restricted own funds of €171.9m (see E.1.3 for details).

SOLVENCY RATIO			
	2019	2018	Variance
Eligible Own funds	716,912	245,258	471,654
Required capital	476,652	148,353	328,300
Surplus	240,259	96,905	143,354
Ratio	150%	165%	-15%

IMPACT OF VOLATILITY ADJUSTMENT ON SOLVENCY RATIO			€ 1,000
	Including Volatility Adjustment	5 ,	Impact Volatility Adjustment
Eligible Own funds	716,912	708,015	8,897
Required capital	476,652	478,977	-2,325
Surplus	240,259	229,037	11,222
Ratio	150%	148%	3%

E.2. SOLVENCY CAPITAL REQUIREMENT AND MINIMUM CAPITAL REQUIREMENT


E.2.1. SOLVENCY CAPITAL REQUIREMENT

Under Solvency II regulations, insurance companies are required to hold a risk-based capital amount for solvency purposes, which is calculated by considering the capital required for the company to withstand a number of different shocks. The next table presents the total solvency capital required (SCR) and breaks this down by risk sub-module.

SOLVENCY CAPITAL REQUIREMENT			€ 1,000
	2019	2018	Variance
Market risk	271,846	76,385	195,461
Counterparty default risk	61,670	7,203	54,467
Life Underwriting Risk	305,319	93,367	211,952
Health Underwriting Risk	100,393	66,268	34,125
Non-life underwriting risk	0	0	0
Diversification	-206,581	-61,297	-145,285
Intangible asset risk	0	0	0
Basic Solvency Capital Requirement	532,646	181,927	350,720
Operational risk	33,678	14,267	19,411
Loss-absorbing capacity technical provisions	-74,912	-47,841	-27,071
Loss-absorbing capacity deferred taxes	-14,759	0	-14,759
Loss-absorbing capacity expected profits	0	0	0
Solvency Capital Requirement	476,652	148,353	328,300

The SCR increased by approximately €328m. A graphical illustration of this increase is as follows:





The reasons for the increase in the SCR are as follows:

- Market risk: Overall the market risk increased by €195.5m. Most of this increase (€170.1m) was due to the Part VII transfer in March 2019. Market movements during 2019 also increased market risk exposures, with reducing interest rates and equity market growth increasing spread risk and equity risk respectively.
- Counterparty Default Risk (CDR): There has been an increase in Counterparty Default Risk of €54.5m, mainly due to the Part VII transfer (€43.9m) relating to additional reinsurance recoverables and bank exposures accepted as part of the transferring business.
- Life risks: Overall the life risks increased by €212.0m. The Part VII transfer accounted for €181.3m of this increase, while new business and market movements resulted in further increases since March 2019.
- Health risks: Health risk has increased by €34.1m. The transferring health business of Irish branch increased this risk by €8.4m. The remaining increases in 2019 related to assumption changes and interest rate reductions.
- Diversification: Diversification has increased by €145.3m during the year. €119m of this increase was due to the Part VII transfer. Further growth in risk modules above resulted in further diversification.
- Loss Absorbing Capacity of Technical Provisions (LACTP): Loss Absorbing capacity of Technical Provisions increased by €27.1m. The Part VII transfer increased this figure by €22.5m, with the addition of the Irish With Profit Fund (IWPF).
- Loss Absorbing Capacity of Deferred Taxes (LACDT): Loss Absorbing capacity of Deferred Taxes increased by €14.8m, of which €6.6m was due to transferring business. The existing Friends First business did not previously generate LACDT, however the net deferred tax of ALPI dac now allows the Company to recognise LACDT on this business also.
- Operational risk: Operational risk increased by €19.4m, which was due to the addition of transferring business increasing Operational Risk by €19.4m.

E.2.2. MINIMUM CAPITAL REQUIREMENT

The MCR is a less onerous capital requirement than the SCR. It represents a minimum level below which the amount of financial resources should not fall. The MCR is based on a linear function of net technical provisions and capital-at-risk. It is subject to a floor of 25% of SCR and a ceiling of 45% of SCR.

The table below shows a comparison of the MCR to the own funds as at 31 December 2019 and 31 December 2018.

			€ 1,000
	2019	2018	Variance
Eligible Own Funds to cover MCR	716,912	245,258	471,654
MCR	127,934	58,719	69,215
Eligible Own Funds / MCR	560%	418%	143%

The MCR has increased by €69.2m during 2019.

E.2.3. USE OF SIMPLIFIED CALCULATIONS

In calculating the life catastrophe risk SCR we use the simplification which is in line with the requirements of Article 96, Commission Delegated Regulation (EU) 2015/35.

E.2.4. UNDERTAKING SPECIFIC PARAMETERS

We do not use undertaking specific parameters.

E.3. DURATION-BASED EQUITY RISK SUB-MODULE

The Company does not use a duration-based equity risk approach.

E.4. INTERNAL MODEL INFORMATION

The Company does not use an internal model.

E.5. NON-COMPLIANCE WITH THE MCR AND NON-COMPLIANCE WITH THE SCR

The Company is compliant with both the Minimum Capital Requirement and Solvency Capital Requirement.

E.6. ANY OTHER INFORMATION

The capital of the Company is monitored on an ongoing basis and the Company continues to maintain strong solvency levels and expects to continue to meet its Solvency Capital Requirements. Notwithstanding this, the COVID-19 pandemic and the associated volatility in financial markets will most likely have an adverse impact on the Company's own funds and solvency ratio. The Company's balance sheet exposure and solvency position has been reviewed and actions are being taken to protect the solvency position and further reduce the sensitivity to economic shocks.

£ 1 000

Additional Information on the COVID-19 global pandemic

On 11 March 2020, the World Health Organisation declared the outbreak of novel coronavirus disease, COVID-19, a global pandemic. Governments in affected areas have imposed a number of measures designed to contain the outbreak, including business closures, travel restrictions, stay at home orders and cancellations of gatherings and events. The spread of COVID-19 has resulted in an economic downturn in jurisdictions in which the Company operates and the global economy more widely, as well as causing increased volatility and declines in financial markets. If the pandemic is prolonged, or further diseases emerge that give rise to similar effects, the adverse impact on the global economy could be deepened and result in further declines in financial markets.

As an insurer ALPI dac is impacted by the COVID-19 pandemic through its life protection products as a result of increased mortality and income protection and critical illness products as a result of increased morbidity. The Company is also keeping its pricing and strategy under review given changes in the risk profile of future new business and expected future investments. The Company's balance sheet exposure has been reviewed and actions are being taken to further reduce the sensitivity to economic shocks. The company continues to maintain strong solvency levels and expects to continue to meet its capital requirements. Since the onset of the pandemic the Company has remained operational, with key activities such as cash payments and transaction processing being maintained, IT systems remaining operational, and employees including frontline customer facing staff being supported to ensure that that we were there to support our customers when they need us most. Notwithstanding the Company's robust capital and liquidity position and the operational and financial actions being taken, the deterioration in the situation has adverse implications arising from the impacts on financial markets, insurance exposures and operations. As the situation is rapidly evolving it is not practicable to quantify the potential financial impact of the outbreak on the Company.

The following summarises the impact of COVID-19 on the information contained within sections A to E of the SFCR where this is considered relevant.

Business and performance

Information presented in Section A of this report represents the performance of the business as reported in the Company's financial statements for the 12-month period to 31 December 2019. As referred to above it is not practicable to quantify the potential financial impact of the outbreak on the company at this stage.

System of governance

The Company's overarching risk management and internal control system is responding well to the challenges of the Covid-19 outbreak and remains intact. Work is in progress in capturing some aspects of change to the control environment to make allowances for the operational constraints. Any moderations are being closely monitored and subject to appropriate governance.

Government travel restrictions and social distancing measures in our major markets have required us to implement contingency plans and changes to some of our operational processes to ensure continued uninterrupted service to our customers, while minimising the impact on the quality of service provided. These plans involve most of our staff being able to work from home, including most of our customer contact staff. The changes to operational processes that have been implemented have been designed to ensure customer service, data protection and staff well-being risks are at a level accepted by Management.

Risk profile

The current process for monitoring the risks, the risk-mitigation techniques in place and the material concentrations of risk to which the business is exposed as a result of COVID 19 for each of the Company's key risk types are as follows:

Underwriting risk

The principal Life underwriting risks impacted by the Covid-19 pandemic are mortality and morbidity risks, where our greatest geographic exposure is to Ireland. We have reinsurance in place to reduce our net exposure to potential losses. We have a high-level

Capital Management

of quota share reinsurance in place on Individual Protection business, and for Group Life protection we have surplus reinsurance for individual claims and a lower-level of quota share reinsurance.

Underwriting procedures on Individual Life Protection products limit our exposure to cohorts of the population at highest risk of Covid-19 (i.e. the elderly and those with pre-existing conditions). While we have greater potential net exposure through Group Life Protection, we are taking pricing actions to limit our potential exposure from new business. We expect there to be some offset to increased protection claims as a result of Covid-19 from reserve releases on our annuity portfolio.

For Income Protection business, while we have some potential exposure to income protection claims arising from Covid-19, our policy terms typically include a deferment period after which benefits become payable to policyholders, and in most cases we expect the deferment period to be longer than the symptomatic period of Covid-19. This materially decreases our exposure.

Market risk

As a result of the financial market impact of Covid-19 we have taken a number of actions to reduce our exposure to equity, property and interest rate risk across all our markets. Actions include purchasing risk-mitigating derivative hedges, asset disposals and reallocations and reducing new business sales in certain markets and products.

Credit risk

As a result of the financial market impact of Covid-19 we have taken a number of actions to reduce our exposure to credit spread and counterparty default risk across all our markets. Actions include purchasing risk-mitigating derivative hedges, asset disposals and reallocation and reducing new business sales in certain markets and products.

Liquidity risk

We continue to closely monitor the Company's liquidity position on a daily basis. Liquidity remains very satisfactory as we have large cash holdings and also hold significant amounts of sovereign bonds which, at the moment, can be quickly converted to cash if required.

Operational risk

Covid-19 is resulting in some changes to operational processes that have been designed to ensure operational risks remain at an acceptable level. Further information is provided in Section B.

Asset management risk

In our asset management processes, our focus has been on our operational processes, including those around liquidity management within our funds, to ensure continued and uninterrupted service to our customers.

Valuation for solvency purposes

The COVID-19 pandemic has resulted in declines in global financial markets with a corresponding impact on the valuation of certain financial assets held at fair value within the Company's balance sheet. The pandemic has also resulted in an increase in volatility in financial markets, increasing the valuation uncertainty of assets and liabilities valued using an alternative method for valuation as described in section D.4. The Company has taken a number of actions to reduce exposure to market risk and credit risk and will continue to monitor its balance sheet exposure.

Technical provisions have been prepared based on conditions and best estimate assumptions at 31 December 2019 and have therefore not been adjusted for any impacts of COVID-19.

Life insurance technical provisions will be impacted through life protection products, as a result of increased mortality, and through income protection and critical illness products, as a result of increased morbidity. These impacts may be offset by a potential reduction in future annuity payments. Life insurance technical provisions will also be impacted by economic movements, although these are expected to be largely matched by movements in financial assets backing the liabilities.



We review the best-estimate assumptions used in the calculation of technical provisions on an ongoing basis and will update them accordingly for the expected impacts of COVID-19. However, given the rapidly evolving nature of the situation, it is not practicable at this stage to quantify the potential valuation impact of the pandemic and related financial market impacts, on the financial assets and technical provisions of the Company.

Capital management

The capital of the Company is monitored on an ongoing basis and the Company continues to maintain strong solvency levels and expects to continue to meet its Solvency Capital Requirements. Notwithstanding this, the COVID-19 pandemic and the associated volatility in financial markets will most likely have an adverse impact on the Company's own funds and solvency ratio. The Company's balance sheet exposure and solvency position has been reviewed and actions are being taken to protect the solvency position and further reduce the sensitivity to economic shocks.



CAUTIONARY STATEMENT

This announcement contains, and we may make other verbal or written 'forward-looking statements' with respect to certain of Aviva's plans and current goals and expectations relating to future financial condition, performance, results, strategic initiatives and objectives. Statements containing the words 'believes', 'intends', 'expects', 'projects', 'plans', 'will', 'seeks', 'aims', 'may', 'could', 'outlook', 'likely', 'target', 'goal', 'guidance', 'trends', 'future', 'estimates', 'potential' and 'anticipates', and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. Aviva believes factors that could cause actual results to differ materially from those indicated in forwardlooking statements in the announcement include, but are not limited to: the impact of ongoing difficult conditions in the global financial markets and the economy generally; the impact of simplifying our operating structure and activities; the impact of various local and international political, regulatory and economic conditions; market developments and government actions (including those arising from the referendum on the UK's membership of the European Union); the effect of credit spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings, on the value of our investments; changes in interest rates that may cause policyholders to surrender their contracts, reduce the value of our portfolio and impact our asset and liability matching; the impact of changes in short or long-term inflation; the impact of changes in equity or property prices on our investment portfolio; fluctuations in currency exchange rates; the effect of market fluctuations on the value of options and guarantees embedded in some of our life insurance products and the value of the assets backing their reserves; the amount of allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; changes in, or restrictions on, our ability to initiate capital management initiatives; changes in or inaccuracy of assumptions in pricing and reserving for insurance business (particularly with regard to mortality and morbidity trends, lapse rates and policy renewal rates), longevity and endowments; a cyclical downturn of the insurance industry; the impact of natural and man-made catastrophic events on our business activities and results of operations; our reliance on information and technology and third-party service providers for our operations and systems; the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; increased competition in the UK and in other countries where we have significant operations; regulatory approval of extension of use of the Group's internal model for calculation of regulatory capital under the European Union's Solvency II rules; the impact of actual experience differing from

estimates used in valuing and amortising deferred acquisition costs ('DAC') and acquired value of in-force business ('AVIF'); the impact of recognising an impairment of our goodwill or intangibles with indefinite lives; changes in valuation methodologies, estimates and assumptions used in the valuation of investment securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and human error or from external events (including cyber attack); risks associated with arrangements with third parties, including joint ventures; our reliance on third-party distribution channels to deliver our products; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of systems errors or regulatory changes on the calculation of unit prices or deduction of charges for our unit-linked products that may require retrospective compensation to our customers; the effect of fluctuations in share price as a result of general market conditions or otherwise; the effect of simplifying our operating structure and activities; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other distributors of our products and services; changes to our brand and reputation; changes in government regulations or tax laws in jurisdictions where we conduct business, including decreased demand for annuities in the UK due to changes in UK law; the inability to protect our intellectual property; the effect of undisclosed liabilities, integration issues and other risks associated with our acquisitions; and the timing/regulatory approval impact, integration risk and other uncertainties, such as non-realisation of expected benefits or diversion of management attention and other resources, relating to announced acquisitions and pending disposals and relating to future acquisitions, combinations or disposals within relevant industries, the policies, decisions and actions of government or regulatory authorities in the UK, the European Union, the US or elsewhere, including the implementation of key legislation and regulation. For a more detailed description of these risks, uncertainties and other factors, please see the Annual report and accounts.

Aviva undertakes no obligation to update the forward looking statements in this announcement or any other forward-looking statements we may make. Forward-looking statements in this report are current only as of the date on which such statements are made.

This Solvency and Financial Condition Report has been prepared for, and only for, the members of the Company, as a body, and no other persons. The Company, its directors, employees, agents or advisers do not accept or assume responsibility to any other person to who this document is shown or into whose hands it may come, and any such responsibility or liability is expressly disclaimed.

Appendices: Quantitative Reporting Templates

The following pages contain Annual Quantitative Reporting Templates (QRTs) for Aviva Life & Pensions Ireland dac as at 31st December 2019. All figures are presented in thousands of Euro with the exception of ratios that are in decimal. Please note that totals may differ from the component parts due to rounding. All items disclosed are consistent with the information provided to the regulators privately.

The following Individual QRTs are publicly disclosed:

Code	Description
<u>S.02.01.02</u>	Balance Sheet
<u>S.05.01.02</u>	Premiums, claims and expenses by line of business
<u>S.12.01.02</u>	Life and Health SLT (Similar to Life Techniques) Technical Provisions
<u>S.22.01.21</u>	Impact of long term guarantees and transitional measures
<u>S.23.01.01</u>	Own Funds
<u>S.25.01.21</u>	Solvency Capital Requirement – for undertakings with Standard Formula
<u>S.28.01.01</u>	Minimum Capital Requirement

APPENDIX 1: BALANCE SHEET

(S.02.01.02)

		Solvency II value
Assets		C0010
Intangible assets	R0030	0
Deferred tax assets	R0040	0
Pension benefit surplus	R0050	0
Property, plant & equipment held for own use	R0060	15,341
Investments (other than assets held for index-linked and unit-linked contracts)	R0070	4,196,689
Property (other than for own use)	R0080	6,234
Holdings in related undertakings, including participations	R0090	470,818
Equities	R0100	258
Equities - listed	R0110	0
Equities - unlisted	R0120	258
Bonds	R0130	3,414,907
Government Bonds	R0140	2,466,473
Corporate Bonds	R0150	948,434
Structured notes	R0160	0
Collateralised securities	R0170	0
Collective Investments Undertakings	R0180	56,430
Derivatives	R0190	182,232
Deposits other than cash equivalents	R0200	0
Other investments	R0210	65,810
Assets held for index-linked and unit-linked contracts	R0220	8,419,747
Loans and mortgages	R0230	260,953
Loans on policies	R0240	1,562
Loans and mortgages to individuals	R0250	0
Other loans and mortgages	R0260	259,391
Reinsurance recoverables from:	R0270	1,860,928
Non-life and health similar to non-life	R0280	0
Non-life excluding health	R0290	0
Health similar to non-life	R0300	0
Life and health similar to life, excluding health and index-linked and unit-linked	R0310	871,437
Health similar to life	R0320	84,251
Life excluding health and index-linked and unit-linked	R0330	787,186
Life index-linked and unit-linked	R0340	989,491
Deposits to cedants	R0350	0
Insurance and intermediaries receivables	R0360	15,192
Reinsurance receivables	R0370	54,005
Receivables (trade, not insurance)	R0380	60,866
Own shares (held directly)	R0390	0
Amounts due in respect of own fund items or initial fund called up but not yet paid in	R0400	0
Cash and cash equivalents	R0410	83,883
Any other assets, not elsewhere shown	R0420	15,550
Total Assets	R0500	14,983,155



Liabilities	
Technical provisions – non-life	R0510
Technical provisions – non-life (excluding health)	R0520
TP calculated as a whole	R0530
Best Estimate	R0540
Risk margin	R0550
Technical provisions - health (similar to non-life)	R0560
TP calculated as a whole	R0570
Best Estimate	R0580
Risk margin	R0590
Technical provisions - life (excluding index-linked and unit-linked)	R0600
Technical provisions - health (similar to life)	R0610
TP calculated as a whole	R0620
Best Estimate	R0630
Risk margin	R0640
Technical provisions – life (excluding health and index-linked and unit-linked)	R0650
TP calculated as a whole	R0660
Best Estimate	R0670
Risk margin	R0680
Technical provisions – index-linked and unit-linked	R0690
TP calculated as a whole	R0700
Best Estimate	R0710
Risk margin	R0720
Contingent liabilities	R0740
Provisions other than technical provisions	R0750
Pension benefit obligations	R0760
Deposits from reinsurers	R0770
Deferred tax liabilities	R0780
Derivatives	R0790
Debts owed to credit institutions	R0800
Financial liabilities other than debts owed to credit institutions	R0810
Insurance & intermediaries payables	R0820
Reinsurance payables	R0830
Payables (trade, not insurance)	R0840
Subordinated liabilities	R0850
Subordinated liabilities not in BOF	R0860
Subordinated liabilities in BOF	R0870
Any other liabilities, not elsewhere shown	R0880
Total Liabilities	R0900
Excess of Assets over Liabilities	R1000

R0510 R0520	C0010 0
-	0
R0520	
110020	0
R0530	0
R0540	0
R0550	0
R0560	0
R0570	0
R0580	0
R0590	0
R0600	4,269,015
R0610	271,010
R0620	0
R0630	247,805
R0640	23,206
R0650	3,998,004
R0660	0
R0670	3,885,398
R0680	112,607
R0690	9,210,642
R0700	0
R0710	9,162,635
R0720	48,007
R0740	0
R0750	11,611
R0760	17,100
R0770	0
R0780	15,426
R0790	96,811
R0800	37,274
R0810	26,562
R0820	0
R0830	10,712
R0840	107,294
R0850	107,294
R0860	918
R0870	106,377
R0880	0
R0900	14,079,392
R1000	903,764

APPENDIX 2: PREMIUMS, CLAIMS AND EXPENSES BY LINE OF BUSINESS

(S.05.01.02.02)

		Line of Business for: life insurance obligations						Life reinsurance obligations		Total
		Health insurance	Insurance with profit participation	Index-linked and unit-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations	Health reinsurance	Life- reinsurance	
		C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written									· · · · · · · · · · · · · · · · · · ·	
Gross	R1410	66,609	6,110	1,094,012	226,859	0	0	0	0	1,393,590
Reinsurers' share	R1420	13,369	76,281	966,298	368,273	0	0	0	0	1,424,221
Net	R1500	53,240	-70,170	127,714	-141,414	0	0	0	0	-30,631
Premiums earned										
Gross	R1510	66,609	6,110	1,094,012	226,859	0	0	0	0	1,393,590
Reinsurers' share	R1520	13,369	76,281	966,298	368,273	0	0	0	0	1,424,221
Net	R1600	53,240	-70,170	127,714	-141,414	0	0	0	0	-30,631
Claims incurred										
Gross	R1610	48,223	133,651	884,074	162,614	0	0	0	0	1,228,561
Reinsurers' share	R1620	11,038	14,346	27,373	64,242	0	0	0	0	117,000
Net	R1700	37,185	119,304	856,701	98,372	0	0	0	0	1,111,561
Changes in other technical provisions										
Gross	R1710	6,051	31,425	-878,030	-52,331	0	0	0	0	-892,886
Reinsurers' share	R1720	-21,925	-96,207	-1,009,083	-229,818	0	0	0	0	-1,357,032
Net	R1800	27,976	127,631	131,052	177,487	0	0	0	0	464,146
Expenses incurred	R1900	13,721	2,449	101,617	42,957	0	0	0	0	160,743
Other expenses	R2500	>	>		>			>	>	0
Total expenses	R2600	>	>		>				>	160,743

APPENDIX 3: LIFE AND HEALTH SLT TECHNICAL PROVISIONS

(S.12.01.02)

		Insurance with	Index-linked and unit-linked insurance			-linked and unit-linked insurance Other life insurance		ance	Total (Life other than	Health insurance (direct business)			Total (Health
		profit participation		Contracts without options and guarantees	Contracts with options or guarantees		Contracts without options and guarantees	Contracts with options or guarantees	health insurance, incl. Unit- Linked)		Contracts without options and guarantees	Contracts with options or guarantees	similar to life insurance)
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0150	C0160	C0170	C0180	C0210
	R0010			\searrow	\langle		\wedge	\langle			\searrow	\sim	
d Finite Re to nole	R0020				\langle			\langle				\checkmark	
	R0030	1,486,417	\ge	8,956,638	205,997	\geq	2,398,980	0	13,048,033	\mathbb{X}	247,805	0	247,805
d Finite Re to	R0080	46,837	\times	813,252	176,238	$\left \right>$	740,349	0	1,776,677	\times	84,251	0	84,251
urance/SPV	R0090	1,439,580	\ge	8,143,386	29,758	\ge	1,658,632	0	11,271,356	$\left \right>$	163,553	0	163,553
	R0100	6,816	48,007		\langle	105,790		\langle	160,614	23,206	\searrow	\sim	23,206
isions													\succ
le	R0110			\wedge	\langle		\wedge	\langle			\wedge	\langle	
	R0120		\succ			\succ				\succ			
	R0130		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~										
	R0200	1,493,234	9,210,642	>>	<	2,504,771	>>	<	13,208,646	271,010	>>	<	271,010

Technical provisions calculated as a whole Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole Gross Best Estimate Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default

Best estimate minus recoverables from reinsurance/SPV and Finite Re - total

Risk Margin

Amount of the transitional on Technical Provision

Technical Provisions calculated as a whole

Best estimate

Risk margin

Technical Provisions - TOTAL

APPENDIX 4: IMPACT OF LONG TERM GUARANTEES AND TRANSITIONAL MEASURES

(S.22.01.21)

		Amount with Long Term Guarantee measures and transitionals C0010	Impact of transitional on technical provisions C0030	Impact of transitional on interest rate C0050	Impact of volatility adjustment set to zero C0070	Impact of matching adjustment set to zero C0090
			00030	C0030	0070	0090
Technical provisions	R0010	13,479,656			-15,406	
Basic own funds	R0020	716,912			8,897	
Eligible own funds to meet Solvency Capital Requirement	R0050	716,912			8,897	
Solvency Capital Requirement	R0090	476,652			-2,328	
Eligible own funds to meet Minimum Capital Requirement	R0100	716,912			8,897	
Minimum Capital Requirement	R0110	127,934			-1,142	

APPENDIX 5: OWN FUNDS

(S.23.01.01)

Basic own funds before deduction for participations in other financial sector as foreseen n article 68 of Delegated Regulation (EU) 2015/35	
Ordinary share capital (gross of own shares)	R0010
Share premium account related to ordinary share capital	R0030
linitial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type undertakings	R0040
Subordinated mutual member accounts	R0050
Surplus funds	R0070
Preference shares	R0090
Share premium account related to preference shares	R0110
Reconciliation reserve	R0130
Subordinated liabilities	R0140
An amount equal to the value of net deferred tax assets	R0160
Other own fund items approved by the supervisory authority as basic own funds not specified above	R0180
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds Own funds from the financial statements that should not be represented by the	
reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	R0220
Deductions	
Deductions for participations in financial and credit institutions	R0230
Total basic own funds after deductions	R0290
Ancillary own funds	
Unpaid and uncalled ordinary share capital callable on demand	R0300
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	R0310
Unpaid and uncalled preference shares callable on demand	R0320
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0330
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360
Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370
Other ancillary own funds	R0390
Total ancillary own funds	R0400
Available and eligible own funds	
Total available own funds to meet the SCR	R0500
Total available own funds to meet the MCR	R0510
Total eligible own funds to meet the SCR	R0540
Total eligible own funds to meet the MCR	R0550
SCR	R0580
MCR	R0600
Ratio of Eligible own funds to SCR	R0620
Ratio of Eligible own funds to MCR	R0640

	Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
	C0010	C0020	C0030	C0040	C0050
			\ge	\searrow	\searrow
R0010	96,559	96,559	\ge	,	
R0030			$\langle \rangle$		
R0040			\searrow		
R0050					
R0070	199,560	199,560	\searrow	\times	\times
R0090					~
R0110		>>			
R0130	-77,578	-77,578	\langle	$\left \right\rangle$	\succ
R0140					
R0160			\langle	\ge	\ge
R0180	498,372	498,372			
	\ge	>	>	\times	\times
R0220		\searrow	\ge	\mathbf{X}	\mathbf{X}
	>	>	\backslash	\ge	\succ
R0230					
R0290	716,912	716,912			
	>	\geq	\geq	>	$>\!$
R0300		\geq	\sim		
R0310		>	>		
R0320		>	\backslash		
R0330					
R0340		$\langle \rangle$	$\langle \rangle$		
		<>	$\langle \rangle$		
R0350		\leq	\sim		
R0360		\geq	\geq		
R0370		>	>		
R0390		$\langle \rangle$	\checkmark		
R0400		\leq	\leq		
	>>	\sim	\leq	\succ	>>
R0500	716,912	716,912			
R0510	716,912	716,912			
R0540	716,912	716,912			
R0550	716,912	716,912			
R0580	476,652	\geq	\geq	\geq	\ge
R0600	127,934	\geq	\geq	\geq	\geq
R0620	150.41%	\geq	\geq	\geq	\geq
R0640	560.38%	>	>	$>\!$	$>\!$



			-
		C0060	
Reconciliation reserve		\ge	
Excess of assets over liabilities	R0700	903,764	
Own shares (held directly and indirectly)	R0710		
Foreseeable dividends, distributions and charges	R0720	-15,000	
Other basic own fund items	R0730	794,490	
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0740	171,852	
Reconciliation reserve	R0760	-77,578	
Expected profits		\ge	
Expected profits included in future premiums (EPIFP) - Life business	R0770	165,374	
Expected profits included in future premiums (EPIFP) - Non- life business	R0780		
Total Expected profits included in future premiums (EPIFP)	R0790	165,374	

APPENDIX 6: SOLVENCY CAPITAL REQUIREMENT

- FOR UNDERTAKINGS ON STANDARD FORUMULA (S.25.01.21)

Market risk
Counterparty default risk
Life underwriting risk
Health underwriting risk
Non-life underwriting risk
Diversification
Intangible asset risk
Basic Solvency Capital Requirement

	Gross solvency capital requirement	USP	Simplifications
	C0110	C0090	C0100
R0010	271,846		
R0020	61,670		
R0030	305,319		
R0040	100,393		
R0050	0		
R0060	-206,581		
R0070	0		>
R0100	532,646		

Calculation of Solvency Capital Requirement

Operational risk

Loss-absorbing capacity of technical provisions

Loss-absorbing capacity of deferred taxes

Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC

Solvency capital requirement excluding capital add-on

Capital add-on already set

Solvency capital requirement

Other information on SCR

Capital requirement for duration-based equity risk sub-module Total amount of Notional Solvency Capital Requirement for remaining part

Total amount of Notional Solvency Capital Requirements for ring fenced funds

Total amount of Notional Solvency Capital Requirement for matching adjustment portfolios

Diversification effects due to RFF nSCR aggregation for article 304

	C0100
R0130	33,678
R0140	-74,912
R0150	-14,759
R0160	0
R0200	476,652
R0210	0
R0220	476,652
R0400	0
R0400 R0410	0 429,330
R0410	429,330

APPENDIX 7: MINIMUM CAPITAL REQUIREMENT

- ONLY LIFE OR ONLY NON-LIFE REINSURANCE ACTIVITY (S.28.01.01)

Linear formula component for non-life insurance and reinsurance obligations

MCR _{NL} Result	R0010	C0010 0			
			J	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
				C0020	C0030
Medical expense insurance and proportional reinsurance			R0020		
Income protection insurance and proportional reinsurance			R0030		
Workers' compensation insurance and proportional reinsura	nce		R0040		
Motor vehicle liability insurance and proportional reinsuranc	e		R0050		
Other motor insurance and proportional reinsurance		R0060			
Marine, aviation and transport insurance and proportional reinsurance		R0070			
Fire and other damage to property insurance and proportional reinsurance		R0080			
General liability insurance and proportional reinsurance		R0090			
Credit and suretyship insurance and proportional reinsurance		R0100			
Legal expenses insurance and proportional reinsurance		R0110			
Assistance and proportional reinsurance		R0120			
Miscellaneous financial loss insurance and proportional reinsurance		R0130			
Non-proportional health reinsurance		R0140			
Non-proportional casualty reinsurance		R0150			
Non-proportional marine, aviation and transport reinsurance	9		R0160		
Non-proportional property reinsurance			R0170		

Linear formula component for life insurance and reinsurance obligations

Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits

Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations

Index-linked and unit-linked insurance obligations

		C0040
MCR _L Result	R0200	127,934

	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
	C0050	C0060
R0210	1,085,313	
R0220	355,286	
R0230	8,173,144	
R0240	1,821,166	
R0250		15,423,055

Overall MCR calculation

		00070
Linear MCR	R0300	127,934
SCR	R0310	476,652
MCR cap	R0320	214,494
MCR floor	R0330	119,163
Combined MCR	R0340	127,934
Absolute floor of the MCR	R0350	3,700
		C0070

Minimum Capital Requirement

	0070
R0300	127,934
R0310	476,652
R0320	214,494
R0330	119,163
R0340	127,934
R0350	3,700
	C0070
R0400	127,934

Г

C0070

